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Abstract

RELATIONSHIP BETWEEN PATINET-HEALTH COACH INTERACTIONS AND
CHANGES IN MARKERS OF GLUCOSE HOMEMSTASIS
By Jason P. Nagy, MS, MT(ASCP)CM
A dissertation submitted in partial fulfilment of the requirements for the degree of doctor of
Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2018
Advisor: Advisor: William J. Korzun, Ph.D., DABCC, MT(ASCP)CM Associate Professor,
Department of Clinical Laboratory Science

Diabetes and insulin resistance are on the rise in the United States. Early detection and
deployment of therapies has allowed for the reversal of pancreatic beta cell damage.
Unfortunately, not all providers can offer the support to facilitating the required life style
modifications. The introduction of clinical health consultants (CHC) as supplemental care has
improved patient health for a variety of chronic diseases. Missing in the literature are studies
investigating the correlation between the number of CHC interactions and improvement in
biomarkers.
The study utilized a non-experimental, retrospective study design to evaluate the
relationship between the use between the use of CHCs and the number of CHC interactions, and
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the mean changes in glucose, hemoglobin A1c, insulin, proinsulin, C-peptide, and 1,5anhydroglucitol, over a one-year period for patients presented with the opportunity to participate
in CHC interactions. The subjects’ follow-up results were compared to their initial results for
each group using the ANCOVA and one-way t-test.
A statistically significant difference was detected between the mean change in BMI and
the use of CHCs (p <0.001). In addition, a statistically significant relationship was identified
between the number of CHC interactions and the magnitude of change in BMI (p< 0.001). No
statistically significant differences were detected for the other study biomarkers. Initial
biomarker values and random error explained a majority of the differences found between the
CHC and non-CHC groups. The use of CHC interactions had a minimum effect on the statistical
models used to compare the CHC and non-CHC groups.

Chapter 1: Introduction

Overview
The study investigated the relationship between the number of clinical health consultant
(CHC) interactions and changes in biomarkers used to evaluate glucose homeostasis related to
diabetes, insulin resistance and beta cell dysfunction. The retrospective study utilized previously
collected data, including glucose, hemoglobin A1c (HbA1c), 1,5-anhydroglucitol (1,5-AG),
insulin, C-peptide, proinsulin, and BMI results, as well as the number of patient-CHC
interactions. The results of this study contributed to the knowledge of the potential efficacy of
CHCs in improving the management and outcomes of patients with diabetes, insulin resistance or
beta cell dysfunction.
Chapter 1 states the study’s purpose, hypotheses, and a summary of health coaching and
data sources with background information on the health risks related to diabetes, and some of its
potential precursors, insulin resistance and beta cell dysfunction. Chapter 2 provides an overview
of diabetes and a literature review of biomarkers related to glucose homeostasis, diabetes, insulin
resistance, and beta cell dysfunction, disease treatment, and the CHC profession. Chapter 3
details the methods used in the study, including sample selection, biomarker testing, and
statistical analysis. Chapter 4 presents the results of statistical analysis and subject demographics.
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Chapter 5 offers a discussion of the results, study limitations, and recommendations for future
studies.
Background
Diabetes is a disorder of glucose metabolism that affects 30.3 million people in the
United States (US), or 9.4% of the American population. Of those, 7.2 million or 23.1% are
reportedly undiagnosed (Centers for Disease Control and Prevention, 2014; Centers for Disease
Control and Prevention, 2017). Diabetes increases the risk of heart disease and stroke, as well as
many other microvascular and macrovascular comorbidities. Improperly managed diabetes can
result in kidney disease, blindness, and amputations. There are four classifications of diabetes:
Type 1 diabetes (T1D) is caused by the autoimmune or other toxic destruction of pancreatic beta
cells. Type 2 diabetes (T2D) is due to a progressive loss of beta cell insulin secretion that follows
the development of insulin resistance. Gestational diabetes mellitus (GDM) develops during the
second or third trimester of pregnancy, with no diagnosis of diabetes prior to pregnancy.
Secondary diabetes is caused by monogenic defects resulting in beta cell dysfunction, including
neonatal and maturity-onset diabetes (Riddle, 2018). Additional causes of secondary diabetes
include disorders of the pituitary, thyroid, or adrenal glands, diseases of the exocrine pancreas, or
drug and chemical related diabetes (Riddle, 2018). Estimates show that of all the individuals
with diabetes, 90-95% have T2D. (Centers for Disease Control and Prevention, 2017). Type 2
diabetes, unlike T1D, is potentially a preventable disease. The development of T2D is not an
acute process, but rather a slowly progressive condition that results in beta cell dysfunction.
Several conditions are associated with the risk of developing T2D including obesity, reduced
exercise, smoking, high blood pressure, and high cholesterol (Centers for Disease Control and
Prevention, 2017).
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Peripheral blood glucose levels are determined by exogenous glucose from the
breakdown of consumed food, and endogenous glucose produced by the liver. Hepatic
conversion of glycogen to glucose, known as glycogenolysis, and glucose production from
amino acids known as gluconeogenesis, occur during times of decreased glucose ingestion such
as sleep and between meals. To compensate for increases in plasma glucose concentrations, in
insulin resistant states, the pancreatic beta cells secrete more insulin, in an effort to enable
peripheral tissues to take up glucose. Over time, the beta cells become exhausted and lose their
ability to produce sufficient insulin. Early detection of this process allows for lifestyle
modifications that can potentially delay or reverse the progression to T2D. Diabetes was ranked
as the seventh leading cause of death in 2015, due to complications such as cardiovascular
disease, stroke, end-stage renal disease, and diabetic ketoacidosis. Early detection and
intervention has the potential to reduce diabetes related morbidity and mortality (Centers for
Disease Control and Prevention, 2017).
The lifestyle modifications required of patients to prevent and/or treat T2D can be
controversial, challenging, and sometimes overwhelming to the patient. The American Diabetes
Association (ADA) recommends that individuals with diabetes should participate in diabetes
self-management education and support (DSMES), medical nutrition therapy (MNT), physical
activity, smoking cessation counseling, and psychosocial care (American Diabetes Association,
2018). The introduction of self-management programs has shown to have a positive effect on
weight loss and lifestyle modification.
CHCs can help facilitate the process of lifestyle modification and treatment compliance
that is required for positive patient outcomes. The development of treatment goals through
discussion between the patient and a CHC is an initial step of therapy. CHC involvement
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provides support for patients secondary to the care received from their providers. The CHCpatient interaction can increase motivation to comply with recommended therapies through
behavior change therapies, identifying underlying factors that may influence an individual’s
motivation, as well as plan nutritional and exercise options. The main objective of a CHC
program is not to treat but to educate the patient and help create the changes needed to overcome
their condition.
Research Problem
Many patients find it difficult to change their lifestyle based on health care provider
recommendations, despite the understanding that it is needed to improve their overall health.
Perceived treatment efficacy, physician trust, worsening of diabetes symptoms, medication cost,
complexity of medication dosage and the side effects of medications are factors that lead to
patient noncompliance (Polonsky & Henry, 2016). These barriers to patient compliance suggest
that doctor-patient interaction is not sufficient for implementing lifestyle changes. Ambivalence
related to motivation and lifestyle changes may also present as barriers (Kehler et al., 2008).
Studies demonstrate that CHC interactions may facilitate and improve adherence to these
lifestyle changes and correlate CHC interactions with changes in markers such as BMI and
HbA1c (Leahey & Wing, 2013; Pettitt, 2013; Wayne & Ritvo, 2014; Wolever et al., 2010). The
mentioned studies only compare a control group to a treatment group with a set number of CHC
interactions. Missing are studies relating the number of CHC interactions to the magnitude of
change in specific biomarkers are lacking. Furthermore, there is no literature on the effect of
CHC interactions on markers of insulin resistance and beta cell dysfunction such as insulin, Cpeptide, and proinsulin, or the more recent glycemic marker, 1,5-AG.
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Purpose of the Study and Research Question
The purpose of this study was to retrospectively examine the relationship between
patients engaging in CHC interactions and changes in glucose, %HbA1c, 1,5-AG, insulin, Cpeptide, proinsulin, and BMI to determine the effectiveness of CHC interactions on potential
change in patient health. The study examined patient results and CHC utilization to determine if
a correlation between the number of CHC-patient interactions and changes in biomarkers over
time exists. The study attempted to answer the research question, is there a relationship between
the changes in patients’ biomarkers of glucose homeostasis and beta cell health and their
interactions with CHCs?
Specific Aims
The study had three Specific Aims:
Specific Aim 1: Determine if there are statistically significant differences between
patients who do or do not participate in CHC interactions in their changes in 1) blood
glucose concentration, 2) %HbA1c, 3) blood 1,5-anhydroglucitol concentration (1,5-AG),
4) blood insulin concentration, 5) blood C-peptide concentration, 6) blood proinsulin
concentration, and 7) body mass index (BMI).
This was addressed by comparing the difference between initial biomarker results and follow-up
results 10-14 months from initial testing, for two groups, 1) those who participated in CHC
interactions, and 2) those who did not. Changes in biomarker values were calculated for each
marker in both the CHC and non-CHC groups and compared statistically.
Specific Aim 2: Determine if statistically significant differences exist in the change in
diabetes and BMI health scores between subjects who did and those who did not interact
with CHCs for glucose and HabA1c.
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Arbitrary health scores were assigned to initial and follow-up testing results. Health scores were
based upon ADA recommended cutoffs for normal, prediabetic, and diabetic values for glucose
and HbA1c, and BMI guidelines for normal, overweight, and obese individuals. The change in
health score was calculated between initial and follow-up testing 10-14 months from initial
testing for two groups, 1) those who participated in CHC interactions, and 2) those who did not.
Group health score differences were then statistically compared.
Specific Aim 3: Determine the relationship between the number of CHC interactions and
magnitude of the change in 1) blood glucose concentrations, 2) % HbA1c, 3) blood 1,5anhydroglucitol (1,5-AG) concentrations, 4) blood insulin concentrations, 5) blood Cpeptide concentrations, 6) blood proinsulin concentrations and 7) body mass index
(BMI).
This was determined by the use of a general linear model to compare the magnitude of change in
each biomarker between subjects with different numbers of CHC interactions. Change in
biomarker values were compared to varying numbers of CHC interactions. Post-hoc Bonferroni
tests of multiple comparisons evaluated the mean change between groups.
Significance of the Study
CHC interactions have shown to be effective in the management and treatment of
diabetes and other related conditions. Studies investigating the effect of CHC interactions have
only utilized the markers of weight loss and HbA1c (Leahey & Wing, 2013; Pettitt, 2013; Wayne
& Ritvo, 2014; Wolever et al., 2010). There is no literature on CHC interactions and potential
change in insulin, C-peptide, proinsulin, and 1,5-AG, nor on the connection between the number
of CHC interactions and the magnitude of the biomarker change. The results of this study
increase the knowledge on the relationship between the number of CHC-patient interactions and
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improvements in biomarkers for diabetes and insulin resistance. This knowledge could help
guide the creation and planning of CHC-mediated therapies to maximize their effectiveness and
efficiency for attaining patient treatment goals. Study findings could also serve as a foundation
for future studies on how to reduce health care costs and improve patient care utilizing CHCs.
Summary of Data Sources and Analysis
Data for this study was gathered from two databases. The laboratory information system
(LIS) at a laboratory in Richmond, VA contained archived patient results for the biomarkers of
interest, starting in April 2012. A query of the LIS provided biomarker results, along with subject
demographics such as age, gender, and body mass index.
The CHC information management system (IMS) database at the same laboratory housed
the dates of patient-CHC interactions. An initial query of the LIS identified patients that met the
study inclusion criteria. Then, a query of the IMS accessed information on CHC interactions for
the subjects identified from the LIS query.
Data from both the LIS and the IMS were merged into a single Microsoft Excel file. The
Principle Investigator imported the data set into Statistical Package for the Social Sciences
(SPSS) for data analysis. The study utilized a one-way analysis of covariance (ANCOVA) and
linear regression. This approach allowed for the determination of within subject differences in
biomarkers, as well as the relationship between CHC-patient interactions, the study independent
variable (IV) and the changes in the markers, the study dependent variables (DVs), while
adjusting for the patient demographics sex, age, and BMI, the study covariables (CV).
Chapter Summary
Chapter 1 provided background on diabetes, the challenges of lifestyle modification, and
how CHCs can help facilitate the change required to improve patient health. Multiple studies
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demonstrate the ability of CHCs to change BMI and %HgbA1c but none address the effects of
CHCs on other makers used to monitor glucose homeostasis and beta cell health. Chapter 2
offers an overview of the pathophysiology of diabetes, biomarkers of glucose homeostasis, and
the potential impact of CHCs on health care outcomes, along with the gaps in literature that this
study hopes to fill. Chapter 3 provides the proposed study’s methodology, including the target
population, sampling strategy, data collection methods and analysis, and potential limitations.
Chapter 4 presents the study findings, while Chapter 5 discusses the study results and describes
the study limitations, and recommendation for future studies.
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Chapter 2: Literature Review

Introduction
Chapter 1 introduced the proposed study including the study purpose, aims, and research
questions. Chapter 2 provides an overview of the pathophysiology of diabetes, biomarkers of
glucose homeostasis, treatments for diabetes, and the clinical health coach professions. First, an
overview of glucose homeostasis and diabetes is presented. Next, information detailing the
markers used in the study is discussed. Finally, information describing CHCs and relevant
studies demonstrating their effect on improving patient health is presented.
Overview
A key to controlling diabetes, and potentially reversing the progression towards T2D, is
the identification of biomarkers of the prediabetic state. Monitoring biomarkers closely linked to
diabetes, insulin resistance, and beta cell function allows for the evaluation of diabetes risk and
control. Measuring glucose, 1,5- anhydroglucitol (1,5-AG), and hemoglobin A1c (%HbA1c)
provide a snapshot of glucose concentration in the peripheral blood at the time of venipuncture,
as well as an estimate of the average glucose concentration over the past two weeks to 3 months.
Abnormal levels of C-peptide, insulin, and proinsulin in the blood alerts providers to the
presence of beta cell dysfunction or death. If detected early, deployment of therapies can
potentially reverse the damage sustained to pancreatic beta cells.
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Adherence to the lifestyle changes required to manage or prevent diabetes is not easy. It
is estimated that a majority of adult diabetics fail to follow physician prescribed treatments for
their disease (Funnell, 2006; Gonzalez, Shreck, Psaros, & Safren, 2014; Willard-Grace et al.,
2013). CHC interactions, when coupled with provider therapies, have shown to have a positive
effect on health outcomes (Appel et al., 2011; Battista et al., 2012; Eakin, Lawler, Vandelanotte,
& Owen, 2007). A common belief in health coaching is that the patient has the ability to adopt
healthy behaviors if given the proper guidance. The professional health coach is an educator, one
whose goal is to provide information and support that elicit change in patient behavior and
physical health.
Glucose Homeostasis
Plasma glucose homeostasis is the result of the dynamic balance between glucose intake
and hepatic synthesis, and the demand for and uptake of glucose by organs and cells including
the brain, gut, liver, kidneys, pancreas, adipocytes and myocytes. The liver and brain take up
glucose directly, not requiring an insulin dependent glucose transporter. The kidneys help
regulate glucose by allowing glucose to be excreted into the urine if the glucose renal threshold
of 180 mg/dL is exceeded. Beta cells, the site of insulin production, are found in a region of the
pancreas called the Islets of Langerhans. Two major types of cells in the Islets of Langerhans, the
alpha and the beta cells, are specific to glucose homeostasis. Alpha cells produce glucagon, a
hormone that stimulates the production of glucose from glycogen, amino acids, glycerol, and
lactate in the liver. Beta cells produce insulin, the hormone responsible for the regulation of
glucose transportation from the peripheral blood into the cell.
Insulin production begins with the synthesis of a parent peptide, preproinsulin. (Chan,
Keim, & Steiner, 1976). Preproinsulin, a protein comprised of approximately 100 amino acids,
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has a short half-life of approximately one minute before it is enzymatically cleaved (Patzelt et
al., 1978). Within the rough endoplasmic reticulum (ER) of the beta cells, the 23 amino acids at
the N-terminal of preproinsulin are removed and two disulfide bonds are formed, resulting in the
formation of proinsulin (Steiner, Cunningham, Spigelman, & Aten, 1967). Proinsulin is then
transported to the Golgi apparatus where it is packaged into storage granules along with
prohormone convertases 1 and 2, and carboxypeptidase H. This conversion is proportionate with
glucose concentration and dependent on the availability of convertase enzymes PC2 and
PC1/PC3 (Nagamatsu, Bolaffi, & Grodsky, 1987). Within the Golgi apparatus, the cleavage of
the 31 amino acid C-peptide from proinsulin forms the hormone insulin. C-peptide and insulin
remain within secretory granules in the beta cells until an increase in blood glucose levels
triggers the release of insulin into the blood.
Glucose stimulation of insulin secretion by the beta cells requires a cascade of events.
First, the glucose transporter 2 (GLUT2) found on the membrane of beta cells transports glucose
from peripheral blood into the beta cell. Glucose then undergoes glycolysis within the beta cell,
generating an increase in ATP. The increase in ATP causes the ligand-gate potassium channel to
close, resulting in an increase in intracellular potassium level and membrane depolarization.
Membrane depolarization allows extracellular calcium to enter the beta cell via voltage-gated
Ca2+ channels, with increasing calcium concentrations signaling the insulin-containing vesicles
to release insulin and C-peptide. Insulin secretion is biphasic, with the first phase of insulin
secretion occurring 2-3 minutes after glucose levels rise and lasting for around 10 minutes. The
second phase of insulin release occurs after the initial, with glucose levels still elevated, and
continues until glucose homeostasis is achieved. Individuals with T2D are shown to have
impaired insulin secretion in the first phase (Cerasi, 1992). Secreted insulin circulates in the
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blood and binds to insulin receptors on the surface of cells such as adipocytes and muscle cells,
stimulating the translocation of the glucose transporter GLUT4 from intracellular storage
vesicles to the cell membrane (Saltiel & Kahn, 2001).
The alpha and beta cells of the pancreas work in tandem to maintain glucose homeostasis.
In addition to facilitating the glucose uptake by peripheral cells, a high ratio of insulin/glucagon
also promotes the storage of glucose as glycogen in the liver and muscle cells. Conversely, when
plasma glucose concentrations fall as in a fasting state, the alpha cells release glucagon, signaling
the liver to convert glycogen to glucose and to promote gluconeogenesis. The inability of the
body to regulate glucose levels in the peripheral blood, caused by lack of insulin, or insulin
resistance, is characteristic of diabetes.
Diabetes
Diabetes is a disorder of glucose metabolism that affects 30.3 million people in the
United States (US), or 9.4% of the American population. Of those, 7.2 million or 23.1% are
reportedly undiagnosed (Centers for Disease Control and Prevention, 2014; Centers for Disease
Control and Prevention, 2017). There are four classifications of diabetes: Type 1 diabetes (T1D)
is caused by the autoimmune destruction of pancreatic beta cells. Type 2 diabetes (T2D) is a
progressive loss of beta cell insulin secretion that is highly correlated with insulin resistance.
Gestational diabetes mellitus (GDM) is a diagnosis of diabetes during the second or third
trimester of pregnancy with no diagnosis of diabetes prior to pregnancy. Secondary diabetes is
due to causes including neonatal and maturity-onset diabetes, disease of exocrine pancreas,
disorders of the pituitary, thyroid, or adrenal glands, pancreatic insufficiency, and drug and
chemical related diabetes (Riddle, 2018) . One of the diagnostic clinical signs of diabetes is the
inability to regulate plasma glucose concentration. Over time, the metabolic abnormalities of
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diabetes can lead to numerous potential microvascular complications such as diabetic
nephropathy and failure, neuropathy, retinopathy, macrovascular complications, and
atherosclerotic vascular disease (coronary, peripheral, cerebrovascular). Uncontrolled diabetes
can also result in a sudden onset of ketoacidosis and hyperosmolar coma, as well as eventual
kidney failure, blindness, and amputations (Forbes & Cooper, 2013).
Type 1 Diabetes
Type I diabetes is characterized by an autoimmune destruction of pancreatic beta cells,
the cells responsible for secreting the hormone insulin. Genetic mutations, specific to class II
human leukocyte antigen (HLA) alleles encoding HLA DRB1*03:01-DQA1*05:01DQB1*02:01 abbreviated DR3 and HLA DRB1*04:01/02/04/05/08-DQA1*03:01DQB1*03:02/04 (or DQB1*02; abbreviated DR4 on chromosome 6p21.31, are highly correlated
with T1D. The HLA regions I and II are responsible for the production of antigens that bind
antigenic peptides involved with T-helper cell presentation. Specifically to T1D, T- cell
presentation of autoantigens typically leads to the production of autoantibodies to proteins found
in the beta cells. It was noted that mutations resulting in HLA DR3/DR4 heterozygotes are more
closely linked to T1D than homozygotes of either haplotype (Nobel & Valdes, 2011). The
antibodies typically found in the plasma of Type 1 diabetics are insulin antigen antibody (IAA),
and anti-glutamic acid decarboxylase (anti-GAD) (Balakhadze, Giorgadze, & Lomidze, 2016).
Type 1 diabetes usually occurs before the age of 15, but may not be diagnosed until later in life.
In addition to their age at the time of diagnosis, patients with adult onset of T1D can be
distinguished from adolescent T1D by higher body mass index (BMI) and C-peptide values
(Törn et al., 2000).

13

There are several stages of T1D (Table 1), with clinical symptoms usually seen at the
later stages (Skylar et al., 2017), (Insel et al., 2015). In stage 1, autoantibodies are present, with
the absence of any clinical signs of diabetes and normal glucose metabolism. During stage 2,
patients begin to have impaired fasting glucose. Fasting plasma glucose (FPG) levels may rise
above the normal cutoff of 99 mg/dL but still below the 126 mg/dL clinical cutoff for diabetes;
or the 2-hour post-prandial sample in an oral glucose tolerance test (OGTT) may be between
140-199 mg/dL. Percent HbA1c values may rise above the normal cutoff of 5.6%, but below the
diabetic cutoff of 6.5%. Patients in Stage 3 display clinical signs of diabetes, polyuria/polydipsia,
with one-third having diabetic-ketoacidosis. Stage 3 is also confirmed with FPG and % HbA1c
values consistent with a diagnosis of diabetes: FPG ≥ 126 mg/dL, a two-hour OGTT ≥ 200
mg/dL, or %HbA1c ≥ 6.5.
Table 1: Type 1 Diabetes Diagnosis by Stage
Stage of Type 1 Diabetes
1

2

3











Diagnostic Criteria
Positive for multiple autoantibodies
No impaired glucose tolerance test
No impaired fasting glucose
Positive for multiple autoantibodies
Dysglycemia:
o FPG 100–125 mg/dL (5.6–6.9 mmol/L)
o 2-h PG 140–199 mg/dL (7.8–11.0 mmol/L)
o A1C 5.7–6.4% (39–47 mmol/mol) or ≥ 10%
increase in A1C
Clinical symptoms
o polyuria/polydipsia, and one-third with diabetic
ketoacidosis (DKA)
Hyperglycemia
Diabetes by standard criteria

Adopted from (Skylar et al., 2017), (Insel et al., 2015), (Cefalu, 2017), (Dabelea et al., 2014)

Controlling T1D involves coordinated management of diet, exercise, and insulin
injections (Riddle, 2018). Therapies designed to normalize glucose metabolism in type 1
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diabetics have secondary benefits of reducing cardiovascular events. The link between glycemic
control and macrovascular disorders is well-established (Klein, 1995; Shamoon et al., 1993).
Type 2 Diabetes
Unlike T1D, T2D is not due to a cellular immune reaction to the beta cells in the
pancreas. Rather, the development to T2D begins with accumulation of fat on muscle, liver, and
pancreatic tissue, resulting in inflammation, insulin resistance, and then eventual beta cell
dysfunction (Riddle, 2018; Skyler et al., 2017). Inflammation can lead to a disruption of the
ability of insulin to activate receptors on the cells in insulin dependent tissues such as muscles.
This phenomenon, termed “insulin resistance,” leads to diminished activity in insulin-mediated
pathways, such as the uptake of glucose (Sinaiko & Caprio, 2012). Cusi et al. concluded that the
ability of insulin to stimulate the phosphatidylinositol 3-kinase (PI 3-kinase) pathway, the
enzyme responsible for the transduction of insulin binding to its receptor and the recruitment of
glucose transport proteins to the surface of cells, was reduced in obese patients and almost
undetectable in patients with T2D (Cusi et al., 2000). The reduction of glucose transport into the
cells results in increased plasma glucose concentrations.
Individuals with insulin resistance can have glucose concentrations and % HbA1c that are
still below the diabetic diagnostic threshold. Protracted hyperglycemia due to insulin resistance
signals pancreatic beta cells to secrete more insulin, leading to increases in the beta cell products
proinsulin, insulin, and C-peptide in the blood. The state of insulin resistance with mild
hyperglycemia may be present for many years before beta cell damage is clinically apparent.
When the beta cells can no longer produce enough insulin to maintain FPG and %HbA1c within
normal levels, the diagnostic threshold of prediabetes are crossed. The American Diabetes
Association (ADA) and the International Expert Committee on the Diagnosis and Classification
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of Diabetes Mellitus have recognized this group of individuals whose glucose levels do not meet
criteria for diabetes as “prediabetic” (The Expert Committee on the Diagnosis and Classification
of Diabetes Mellitus, 2003). Prediabetes is not considered its own disease state; patients with
prediabetes are at an increased risk for developing T2D and cardiovascular complications
(Armstrong, 2017).
At this point, beta cell function continues to deteriorate without lifestyle adjustments.
When patients in a prediabetic state are identified, interventions such as lifestyle changes can
delay or even prevent progression to T2D. When 80% of beta cell function is lost, circulating
levels of insulin, proinsulin, and C-peptide start to decrease, eventually leading to levels of
hyperglycemia and %HgbA1c that are consistent with T2D (DeFronzo & Abdul-Ghani, 2011). If
interventions fail to preserve the remaining beta cells, the patient will require exogenous sources
of insulin, similar to Type 1 diabetics (Weir & Bonner-Weir, 2004).
Figure 1 illustrates the chronological relationships between various parameters of the
derangement of glucose homeostasis along the progression to T2D.

Figure 1: Diabetes Progression Timeline
Duplicated with permission, (Ramlo-Halsted & Edelman, 1999)
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Weir, et al have proposed 5 stages in the progression to T2D:


Stage 1, Compensation. The first stage is characterized by the ability to maintain
normal blood glucose concentrations but only because of an increase of insulin
production. Compensation is thought to entail an increase in beta cell mass to
accommodate the increase in insulin. Monitoring blood glucose concentrations or
%HgbA1c would not indicate the presence of insulin resistance or potential
progression towards T2D.



Stage 2, Stable adaptation. Beta cells can no longer maintain normal glucose
levels in the peripheral blood, and patients demonstrate sustained elevated postprandial glucose, and fasting blood glucose levels up to 130 mg/dL, along with
impaired glucose stimulation of insulin secretion. Patients may avoid progression
to Stage 3 for many years, with lifestyle changes such as diet and exercise
(Knowler et.al., 2002).



Stage 3, Unstable Early Decompensation. Functional beta cells have declined to a
level where there is inadequate response to elevated glucose concentrations, and
glucose levels rise to as high as 350 mg/dL in a short period of time.



Stage 4, Stable Decompensation. Beta cell size and mass that is half of that in
normal individuals. Most patients with T2D can remain in Stage 4 for the rest of
their lives, with a sufficient amount of insulin production to prevent diabetic
ketoacidosis.



Stage 5, Severe Decompensation. The loss of beta cells is so severe that patients
become susceptible to ketoacidosis and are totally dependent on insulin for
survival. Glucose levels are typically >350 mg/dL (Weir & Bonner-Weir, 2004).
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According to the ADA, a diagnosis of diabetes is made if one of any of the following
conditions is demonstrated on more than one occasion: [1] HbA1c is ≥ 6.5%, [2] fasting glucose
is ≥ 126 mg/dL, [3] the two-hour specimen from an oral glucose tolerance test (OGTT) is ≥
200 mg/dL or [4] the patient has a random blood glucose concentration > 200 mg/dL along with
the clinical symptoms of diabetes (Cefalu, 2017). Patients without clinical signs of diabetes and
whose lab results do not meet the criteria for diabetes may be classified as prediabetic, according
to the ADA, if they demonstrate fasting blood glucose concentrations between 100 mg/dL and
125 mg/dL, %HbA1c concentrations between 5.7 and 6.4%, or a two-hour post-prandial blood
specimen from an OGTT between 140 mg/dL and 199 mg/dL (Cefalu, 2017). In 2015, it was
estimated that in the US, 37% of adults over 18 and 48.3% of all adults aged 65 and above are
prediabetic (Centers for Disease Control and Prevention, 2017). It is recommended that
individuals who are asymptomatic have their blood glucose and %HgbA1c measured if they
have a BMI greater than 25 kg/m2 or have other risk factors for diabetes such as reduced
exercise, a family history of diabetes, or a less than healthy lifestyle (American Diabetes
Association, 2013). Increases in age and BMI are highly correlated with the occurrence of T2D
(American Diabetes Association, 2013);(Centers for Disease Control and Prevention, 2017).
Gestational Diabetes
Gestational diabetes is the diagnosis of diabetes in the second or third trimester of
pregnancy, in the absence of T1D or T2D prior to conception. Gestational diabetes is associated
with an increased risk of perinatal complications and maternal T2D after delivery (Riddle, 2018).
The exact pathophysiology of GDM is unknown; however, obesity and increased BMI are highly
correlated with the development of GDM (Ehrenberg, Dierker, Milluzzi, & Mercer, 2002;
Hedderson, Williams, Holt, Weiss, & Ferrara, 2008). Testing for GDM usually occurs at 24-28
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weeks gestation in women with no prior diagnosis of diabetes. If a woman is diagnosed with
GDM, she is tested again at 4-12 weeks postpartum for persistent diabetes. Testing can be done
two ways, a one-time dose of 75g glucose OGTT or a two-step 50g OGTT screen followed by a
100g OGTT for positive screen results. The one-time 75g OGTT cutoffs for diagnosis of GDM
are a fasting glucose ≥ 92 mg/dL, 1 hour glucose ≥ 180 mg/dL, or a 2 hour glucose ≥153 mg/dL.
According to the ADA, glucose measurements of ≥ 130 mg/dL, 135 mg/dL, or 140 mg/dL at 1
hour following a 50g load are all acceptable positive cutoffs, with the 140 mg/dL cutoff being
the most specific (70-88%) and the 130 mg/dL cutoff being the most sensitive (69-89%) (Riddle,
2018). The cutoff used is dependent on the physician’s preference. Patients would then receive a
100 g OGTT at their next visit. There are two criteria for 100g OGTT cutoffs, the CarpenterCoustan and the National Diabetes Data Group (NDDG). According to Carpenter-Coustan, the
diagnosis of diabetes is made if at least two of the following are met: Fasting glucose ≥ 95
mg/dL, a 1 h glucose ≥180 mg/dL, a 2 h glucose ≥ 155 mg/dL, a 3 h glucose ≥ 140 mg/dL.
According to the NDDG, a diagnosis of diabetes is made if fasting glucose is ≥ 105 mg/dL, 1
hour glucose ≥190 mg/dL, 2 hour glucose ≥ 165 mg/dL, or 3 hour glucose ≥ 145 mg/dL
following the 100 g load. Table 2 illustrates the two different methods for diagnosis GDM.
Table 2: Criteria for GDM Diagnosis

One Step strategy 75-g OGTT

Fasting
1h
2h
3h

92 mg/dL
(5.1 mmol/L)
180 mg/dL
(10 mmol/L)
153 mg/dL
(8.5 mmol/L)
N/A

Two-Step Testing
50-GOGTT ≥ 130 mg/dL (7.5 mmol/L) positive
100- OGTT Cut-off
Carpenter-Coustan
NDDG
95 mg/dL
105 mg/dL
(5.3 mmol/L)
(5.8 mmol/L)
180 mg/dL
190 mg/dL
(10.0 mmol/L)
(10.6 mmol/L)
155 mg/dL
165 mg/dL
(8.6 mmol/L)
(9.2 mmol/L)
140 mg/dL
145 mg/dL
(7.8 mmol/L)
(8.0 mmol/L)

Classification and Diagnosis of Diabetes (Riddle, 2018)
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Treatment for gestational diabetes could include a lifestyle changes such as a modified diet and
exercise schedule, along with glucose monitoring and/or insulin injections to assist reaching
glycemic targets of fasting glucose < 95 mg/dL (Riddle, 2018).
Diabetes Due to Other Causes
Causes for secondary diabetes include single gene mutations causing neonatal diabetes, a
diagnosis of diabetes within the first six months of life, and maturity-onset diabetes of the young
(MODY), a condition typically characterized by impaired insulin secretion and hyperglycemia
before the age of 25. Specifically, MODY is the result of defective insulin production in
response to increases in plasma glucose concentration (Fajans & Bell, 2011). In both neonatal
and MODY, the cause of genetic mutation can be spontaneous, or the result of autosomal or
recessive gene inheritance. Due to their unusual circumstance, these types of diabetes usually
require the involvement of a diabetes specialist to determine the best treatment routine. Disease
of exocrine pancreas such as cystic fibrosis and pancreatitis are also causes of secondary
diabetes. Additionally, disorders in the pituitary, thyroid, or adrenal glands, pancreatic
insufficiency, and drug or chemical interactions can cause secondary diabetes (Riddle, 2018).
Treatments for Diabetes
Lifestyle choices such as smoking, lack of exercise, diets high in carbohydrates and low
in fiber can contribute to the development towards T2D. If detected early, lifestyle modifications
such as regular exercise, lower energy intake, better food choices, smoking cessation, and
medication can diminish or halt disease progression and improve cells’ sensitivity to insulin
(American Diabetes Association, 2018; National Diabetes Information Clearinghouse, 2014).
Furthermore, Godsland et al. concluded that loss of beta cell function is highly correlated with
increases in age and BMI (Godsland, Jeffs, & Johnston, 2004). Unfortunately, reversal of overt
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T2D is much more difficult. By the time diagnostic glycemic thresholds of hyperglycemia have
been crossed, severe beta cell damage has already occurred. It is recommended to develop and
maintain a healthy lifestyle early, before beta cell damage becomes irreversible. A 2005 study
reported that individuals who underwent intensive lifestyle modifications significantly improved
insulin sensitivity and beta cell preservation over the course of one year (The Diabetes
Prevention Program Research Group, 2005). Diabetes self-management, such as self-monitoring
of blood glucose levels and diet selection, combined with education, and support, are correlated
with increases in diabetes knowledge and self-care (Haas et al., 2012).
Once a patient is identified as being at risk for progression to T2D, education and
support are important components, along with lifestyle changes, of a plan to reverse the process.
However, patients often lack the ability to stick to a treatment plan. Gonzales pointed out that
less than half of adult diabetics maintain an HbA1c level below recommended glycemic goal,
mostly due to non-adherence to medication (Gonzalez, Shreck, Psaros, & Safren, 2014).
Furthermore, less than 10% of individuals follow physician guidelines to stop smoking or lose
weight (Haynes, 2001). Specifically, less than 17% of patients with T2D reportedly follow
providers’ prescribed regimens for diet, exercise, medication taking, glucose testing, and
appointment keeping (Funnell, 2006; Skovlund & Peyrot, 2005). Data suggests that dependence
solely on physicians’ directives is not sufficient to successfully manage T2D. Barriers to
compliance include: patient’s perceived treatment efficacy, worsening of diabetes symptoms and
side effects of medication, treatment complexity and convenience, cost of treatment, concerns
related to negative effects of the medication being prescribed, and /or physician trust (Polonsky
& Henry, 2016). In their 2001 study, Claxton et al. concluded that adherence to diabetes
medication is inversely related to the number of daily doses. They found that the percent
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adherence dropped from 79% with a single dose per day to 51% for medications requiring four
doses per day (Claxton, Cremer, & Pierce, 2001). In 2009, Mann et al investigated the
correlation of disease and medication beliefs and drug regimen adherence. Their survey of poorly
adherent subjects concluded that some barriers to adherences include beliefs that [1] medication
is needed only at times of hyperglycemia (56%, p=0.006), [2] is not needed when their glucose
is normal (53%, p=0.02), [3] when the side effects would likely be severe (42% of poorly
adherent subjects, p=0.001), and [4] that the medications instructions made them too difficult to
take (74% of poorly adherence subjects, p=0.001) (Mann, Ponieman, Leventhal, & Halm, 2009).
Examples of some currently available medications include those to help control glucose
levels by promoting insulin secretion (sulfonylureas and meglitinides), by reducing hepatic
glucose production (biguanids), by reducing the reabsorption of glucose by kidney (SGLT2
inhibitors), or by reducing the absorption of glucose in the intestines (a-Glucosidase Inhibitors).
Medications may not be needed for all patients. Lifestyle modifications, such as a low-calorie,
low-fat recommended diets, and moderate intensity exercise for at least 150 minutes per week,
have the potential to improve glucose control in patients with T2D (American Diabetes
Association, 2018). Nondiabetic patients who adhere to these recommendations saw greater than
50% reduction in the occurrence of T2D, compared to only 31% of those only taking metformin,
an oral drug used to help control plasma glucose levels by reducing hepatic glucose production,
for 2.8 years (National Institute of Health, 2002). In addition to diet, a structured and monitored
moderate exercise program alone may lead to improvement of glucose metabolism (Liao et al.,
2015). Torjensen et al. investigated the effect of three interventions, diet alone, diet and exercise,
and exercise alone on the reduction of insulin resistance. At the end of one year, they found that
the all interventions group showed a decrease in fasting glucose; but the diet and exercise
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intervention group showed the greatest (0.3 mmol/L reduction compared to the control group
(0.0 mmol/l reduction) (p < 0.0010) (Torjesen et al., 1997).
CHC interventions, especially the promotion of increased physical activity, may have an
impact on the improvement of 1,5-AG levels in patients. Honda et al. demonstrated that a post
prandial exercise routine consisting of stair climbs (two sets) for three minutes, increased
peripheral blood 1,5-AG concentrations (Honda et al., 2017). Measuring plasma 1,5-AG
concentrations may serve as a marker for the success of CHC intervention to change lifestyle
behaviors that lead to improved glycemic control.
Lifestyle modifications used to improve glucose homeostasis may also reduce insulin
resistance, as evidenced by lower insulin levels. In their inpatient study, Boden et al. concluded a
low carbohydrate diet reduced insulin as well as glucose concentrations in the plasma of patients
with T2D (Boden, 2008). Trap et al. demonstrated that high intensity intermittent exercise (HIIE)
significantly reduced fasting plasma insulin concentrations in women compared to the control
and steady state exercise groups (p < 0.05) ( Trapp, Chisholm, , Freund, & Boutcher, 2008).
Rice also demonstrated that a combination of reduced caloric intake and exercise has a greater
effect on reducing insulin levels as opposed to diet alone (p< 0.05) (Rice, Janssen, Hudson, &
Ross, 1999).
Treatment of patients with diet, exercise, and medication has been shown to reduce
proinsulin levels. Medication, such as pioglitazone, a thiazolidinedione class drug, increases
insulin sensitivity by increasing glucose transporters 1 and 4, improving glucose uptake by cells,
and reducing circulating glucose, thus lowering the demand of insulin secretion (Smith, 2001).
Kubo found that treatment of patients with T2D with pioglitazone led to a significant decrease in
proinsulin levels from a mean of 24.7 pmol/L to a mean of 14.0 pmol/L (p <0.01) (Kubo, 2002).
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Torjesen et al. compared the effects of three interventions on insulin sensitivity. Subjects were
randomly assigned to a control group, or one of three treatment groups: diet only, exercise only,
or diet and exercise combined intervention. After one year, subjects in all three different
treatment groups showed significantly lower proinsulin levels compared to subjects in the control
group (Torjesen et al., 1997). In addition, the subjects in all three treatment groups showed
significantly lower plasma C-peptide concentrations compared to those in the control group (p
value of < 0.0011 for all three intervention groups) (Torjesen et al., 1997).
Glucose
Glucose is a monosaccharide that is utilized by every cell in the body to drive the
phosphorylation of ADP to ATP. Plasma glucose may originate from the digestion of complex
carbohydrates in food, the breakdown of glycogen in the liver, and gluconeogenesis, the
production of glucose from non-carbohydrate substances by the liver and kidney (Krebs, 1964).
Additionally, in times of prolonged starvation, liver and kidney glucose production is equal in
proportion (Owen et al., 1969).
The body normally maintains circulating blood glucose levels between 70 - 99 mg/dL
when in a fasting state. In patients with diabetes or prediabetes, prolonged exposure to higher
than normal levels of glucose in the peripheral blood have been linked to both microvascular and
macrovascular complications. These can include nephropathy, neuropathy, retinopathy,
cardiovascular disease and peripheral arterial disease. In their 2005 study of normal male
patients, Tirsho et al. concluded higher fasting plasma glucose levels within the normal glycemic
range are at an increased risk for T2D (Tirosh et al., 2005).

24

Hemoglobin A1c
Hemoglobin, the principal cytoplasmic protein of red blood cells (RBC), is a tetramer
consisting of four globin chains, each one having a heme group bound to the polypeptide
structure. Normal adult hemoglobin A (HgbA) consists of two alpha chains and two beta chains.
Within each heme group, one ferrous iron binds to four nitrogen atoms within the heme
structure. The ferrous iron binds reversibly with oxygen. In a non-enzymatic reaction, glucose
can form a Schiff base with the N-terminal valine of the beta chains at a rate directly
proportional to the concentration of glucose in the blood (Brownlee, 1995). The product of this
glycation reaction can undergo an Amadori rearrangement to form a stable covalent 1-amino-1deoxy-2-ketose derivative of hemoglobin A, also known as HbA1c.
Once hemoglobin is glycated, it remains glycated for the life of the erythrocyte in which
it is contained. Since the rate of HbA1c production is directly proportional to the peripheral
blood glucose concentration, the higher the average concentration of glucose in the blood, the
higher the percent of HgbA that is glycated at any point in time. The average lifespan of normal
RBCs is 120 days. Therefore, the percent of HbA1c in a blood specimen reflects the integrated
average of blood glucose concentrations over the previous 3 months. As with FPG, the risk of
diabetes related microvascular and macrovascular complications in patients with T2D is
positively associated with %HbA1c levels >6.0% (Stratton et al., 2000). Furthermore, the risk of
myocardial damage increases as patients move from normal to a prediabetic state, to a diagnosis
of diabetes (Selvin et al. 2014). Other hemoglobins, such as hemoglobin A2, hemoglobin S, and
hemoglobin E can also be glycated; but since their half-life is not the same as HbA1c, the
reference range for % HbA1c cannot currently be used to assess glycemic control in patients
with these variant hemoglobins. The %HbA1c at any point in time has been shown to be a better
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indicator of average blood glucose concentrations over time than periodically measured blood
glucose concentrations; therefore, a better indicator of the risk for the long-term complications of
persistently elevated plasma glucose concentrations (International expert committee report on the
role of the A1C assay in the diagnosis of diabetes, 2009). Treatments aimed at lowering glucose
in turn affect %HbA1c over time. As average blood glucose concentrations decrease, the
%HbA1c decreases proportionately.
There are limitations if only %HbA1c is used to monitor patients for the risks of
complications of diabetes and/or response to diabetes therapy. Variations in RBC lifespan can
influence the cumulative glycation of HgbA, and can alter the %HbA1c (R.M. Cohen et al.,
2008). This could give %HbA1c values that do not quantitatively reflect average blood glucose
concentration. The %HbA1c could be falsely elevated in patients with iron deficiency anemia
and asplenia due to the longer lifespan of these RBCs (Christy, Manjrekar, Babu, Hegde, &
Rukmini, 2014);(Radin, 2014). Falsely decreased levels may be seen with conditions resulting
from increased RBC turnover such as acute or chronic blood loss, splenomegaly, and red cell
transfusion (Radin, 2014).
1,5-anhydroglucitol
Another method of monitoring elevated or postprandial blood glucose concentration is to
measure 1,5-anhydroglucitol (1,5-AG) concentrations in blood. 1,5-AG (Figure 2) is a dietary
monosaccharide that closely resembles the molecular structure of glucose
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Figure 2: Glucose and 1,5- anhydroglucitol molecules

Concentrations of 1,5-AG in blood can provide an indication of hyperglycemia and
postprandial glycemia. Normally, 1,5-AG is removed from the blood by glomerular filtration,
and reabsorbed by the renal tubules in the kidney. Most 1,5-AG is returned to the blood via renal
tubular reabsorption, with very little excreted in the urine, thus maintaining a constant level in
the blood. In patients with normal glucose homeostasis, the concentration of 1,5-AG in blood
remains stable over a 24-hour period, with minimal variation due to short-term dietary changes
(Yamanouchi et al., 1987). In states of hyperglycemia, glucose competes with 1,5-AG for renal
tubular reabsorption. Due to the similarity in structure, once plasma glucose concentrations
exceed the renal threshold for reabsorption of approximately 180 mg/dL, 1,5-AG is also excreted
in the urine with a concomitant decrease in plasma 1,5-AG concentrations.
Plasma 1,5-AG concentration is inversely correlated with both FPG concentration and
short-term average blood glucose concentrations. In their 1996 study of 56 subjects with newly
diagnosed non-insulin dependent diabetes mellitus (NIDDM), Yamanouchi et al. reported slight
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changes in glycaemia can be detected within two weeks using serum 1,5-AG as a marker, sooner
than with %HbA1c or serum fructosamine concentration. Subject’s 1,5-AG levels dropped from
7.4 µg/mL to 4.8 µg/mL (p=0.673), while A1c values showed no significant change (P= 0.001)
(Yamanouchi et al., 1996). Dungan et al (2006). were able to demonstrate, using a continuous
glucose monitoring system, that plasma 1,5-AG concentrations can be used as indicators of
glucose change after a meal in patients in either a prediabetic state or with overt diabetes
(Dungan et al., 2006). Akanuma et al. reported plasma 1,5-AG concentrations in newly
diagnosed diabetic patients to be 1.9 ± 1.8 µg/mL, compared to 13.4 ± 28.3 µg/mL in healthy
subjects (Akanuma, Morita, Fukuzawa, Yamanouchi, & Akanuma, 1988). In addition,
decreasing plasma 1,5-AG concentrations have been correlated with the risk of developing T2D.
In their 2012 study, Juraschek et al, evaluated serum 1,5-AG and the incidence of diabetes over a
three-year period. They concluded that higher baseline quartiles of 1,5-AG were associated with
a lower incidence of diabetes (Juraschek, Steffes, Miller, & Selvin, 2012).
Insulin
Insulin, a 6 kilodalton (kDa) peptide hormone consisting of 51 amino acids, is the
primary regulator of glucose uptake by peripheral cells. It is composed of one α-chain and one βchain connected by two disulfide bonds. Insulin is secreted by the beta cells, located in the Islets
of Langerhans of the pancreas, in response to elevated plasma glucose concentrations. The
binding of insulin to insulin receptors on the surface of insulin-dependent cells stimulates the
translocation of the glucose transporter GLUT4 from intracellular storage vesicles to the cell
membrane, facilitating the uptake of glucose. Increases in plasma insulin concentration, in
concert with decreases in plasma glucagon concentrations, also inhibit hepatic gluconeogenesis.
(Saltiel & Kahn, 2001).
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Normal fasting serum insulin concentrations range from 3-9 µU/mL or 20.8 – 62.5
pmol/L. In cases of frequent hyperglycemia, prolonged exposure of the body’s cells to insulin
can lead to a desensitization of the cellular receptors to insulin, leading to a state of “insulin
resistance.” The decreased ability of cells to take up glucose from peripheral blood exacerbates
the hyperglycemia. Beta cells initially compensate by producing additional insulin, with
hyperinsulinemia an indication of insulin resistance. Over time, insulin levels continue to rise in
response to extended elevated plasma glucose concentrations. The increased demand for insulin
results in beta cell stress, with prolonged beta cell stress eventually lead to beta cell death. As
beta cell death occurs, the pancreas loses the ability to produce insulin, indicated by
hyperglycemia with hypoinsulinemia.
C-Peptide
C-peptide is the 31- amino acid peptide released from proinsulin by prohormone
convertases 1 and 2 during the formation of insulin in the storage vesicles of the pancreatic beta
cells. Insulin and C-peptide are secreted into the portal vein in equimolar concentrations, but the
concentration of C-peptide in peripheral blood is greater than that of insulin. This is due to Cpeptide not undergoing first-pass metabolism in the liver as insulin does. As a result, the half-life
of C-peptide is around 30 minutes, six times that of insulin (Polonsky et al., 1986). The majority
of C-peptide is metabolized and excreted by the kidney (Zavaroni et al., 1987).
C-peptide may have a physiological effect on cell recognition of glucose and may
facilitate some transmembrane movement of glucose into cells. Renal tubule cells possess
numerous C-peptide binding sites. C-Peptide is involved in numerous cell signaling pathways, as
well as protecting kidney cells from tumor necrosis alpha, a contributing factor in diabetic
nephropathy (Hills & Brunskill, 2009). In addition, C-peptide has several downstream effects

29

upon binding to cell surface components, including raising intracellular calcium levels,
increasing PI-3-kinase activity, and stimulation of the Na+/K+ ATPase, the protein complex
responsible for using energy generated from the hydrolysis of ATP to facilitate the counter
transport of NA+ and K+ across plasma membranes (Hills & Brunskill, 2008). In their 2012
study, Patel et al. correlated fasting serum C-peptide levels with cardiovascular risk. They
concluded that nondiabetic patients in the highest quartile (72%) had a significantly higher
incidence of cardiovascular death, compared to those in the lowest quartile (60 %) (Patel,
Taveira, Choudhary, Whitlatch, & Wu, 2012). In addition, Heding and Rasmussen concluded in
their study that mean C-peptide levels of 0.37 nmol/L or 1.11 ng/dL were indicative of normal
subjects, and mean C-peptide of 0.86 nmol/L or 2.6 ng/mL were correlated with maturity onset
of diabetes (Heding & Rasmussen, 1975).
Plasma C-peptide concentrations may be used to evaluate beta cell function. In their
systematic review, Jones concluded that C-peptide is useful in evaluating insulin secretion and
diabetes management (Jones & Hattersley, 2013). C-peptide allows for the evaluation of beta
cell function in patients taking exogenous insulin. Serum insulin concentrations include both
endogenous and exogenous insulin, whereas C-peptide concentrations reflect only the
endogenous activity of the beta cells (Clark, 1999). Plasma C-peptide concentrations also aid in
the differentiation between T1D and T2D, with higher values associated with insulin secretion
and the progression to T2D (Service, Rizza, Zimmerman, & Dyck, 1997).
Proinsulin
Proinsulin is formed from the polypeptide preproinsulin. Within the endoplasmic
reticulum of the beta cells, the 23 amino acid-residue signal peptide of preproinsulin is removed
to form proinsulin. The primary structure of proinsulin consists of the sequence of amino acids
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that eventually become the alpha and beta chains of insulin, along with the C-peptide fragment.
Most of the proinsulin is converted to insulin and C-peptide in the storage vesicles of the beta
cells, and only a small amount of proinsulin is released in to the peripheral blood. However,
plasma concentrations of proinsulin are usually higher than insulin. Proinsulin has a much longer
half-life, around 17 minutes, compared to insulin, with a half-life of around 5 minutes (Starr &
Rubenstein, 1974). In addition, proinsulin has a much lower hepatic extraction than insulin
(Horwitz, Starr, Mako, Blackard, & Rubenstein, 1975).
In states of insulin resistance, there is an increased demand for insulin. Proinsulin levels
may rise in the peripheral blood due to impaired formation of C-peptide and insulin. This is due
to the increased compensatory synthesis of preproinsulin and the decreased availability of beta
cell carboxypeptidase H, the enzyme needed to cleave the amino acids from the C-terminal of
proinsulin to form insulin and C-peptide (Pfützner, Pfützner, Larbig, & Forst, 2004). Research
has shown that fasting plasma proinsulin concentrations can predict the conversion from
impaired glucose tolerance (IGT) to T2D along with the severity of hyperglycemia. (Nijpels,
Popp-Snijders, Kostense, Bouter, & Heine, 1996). Elevated plasma proinsulin concentrations can
be found in states of glucose intolerance, even in the absence of elevated plasma C-peptide or
insulin concentrations (Krentz, Clark, Cox, & Nattrass, 1993). Vangipurapu et al. reported a
correlation between increased plasma proinsulin concentrations and the worsening of
hyperglycemia and conversion to T2D (Vangipurapu et al., 2015). Saad et al. reported that the
degree of proinsulin elevation was directly related to the severity of hyperglycemia (Saad et al.,
1990). This was subsequently confirmed by Røder et al (Røder, Porte, Schwartz, & Kahn, 1998).
Furthermore, elevated proinsulin levels have been shown to be a risk factor for premature
coronary artery disease (CAD) (Katz, Ratner, Cohen, Eisenhower, & Verme, 1996). In addition,
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Pfutzner et al. concluded that fasting proinsulin levels above 10 pmol/L were associated with
insulin resistance (Pfützner et al., 2004).
The previous sections described the various markers of the progression to diabetes.
Although there is evidence that patients can achieve improvements in biomarkers of glucose
homeostasis through lifestyle modification, these changes are not easily accomplished. The next
section describes the various treatments for diabetes and prediabetes, the CHC profession, and
the potential impact of CHCs on biomarker results.
Health Coaches
Health or wellness coaches have become popular as part of the movement towards
preventative health. Three types of health coaches exist: peer, mentor, and professional (Leahey
& Wing, 2013). Peer coaches are individuals with the same condition as the patient, while
mentors have overcome the affliction of interest. Both peers and mentors can help others achieve
similar success by sharing experiences of what worked for them at different times of their
disease/condition. The third type is a professional health or wellness coach. Professional health
coaches, described as clinical health consultants (CHC) in this study, receive formal training by
means of procedure review, training checklist completion, and attendance of required training
seminars. CHCs are also often certified in facilitating support by organizations such as the
National Society of Health Coaches, the American Council on Exercise, or the Wellness School
of Coaching. The role of a CHC is not to treat the patient, but rather to supplement the work of
physicians with information and support (Leahey & Wing, 2013). The CHC is an educator whose
overall goal is eliciting change in a patient’s behavior and physical health.
A search of the available literature demonstrates that patient-health/wellness coach
interactions reduce weight and %HbA1c concentration in diabetic patients, and have a major
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impact on improving health behaviors (Liddy, Johnston, Nash, Ward, & Irving, 2014). Various
programs involving repetitive education and support outlets influence positive health outcomes
(Haas et al., 2012; Liddy et al., 2014), (Leahey & Wing, 2013), (Wayne & Ritvo, 2014).
Professional education, especially when delivered frequently and over a long period, may yield
more of the desired patient outcomes for those with T2D (Loveman, Frampton, & Clegg, 2008).
In a 2007 study, Ko monitored the %HbA1c of subjects who participated in 30 hours of diabetes
education for five days, followed by a three-hour reinforcement educational session during
annual follow-up sessions over a course of four years. They found that the study group had lower
mean %HbA1c values (7.9%), compared to their control group, those who only received an
initial education of four hours with no annual reinforcement during follow-up visits, ( 8.7%), (P<
0.05) (Ko et al., 2007).
A common belief among all coaching approaches is that the patient has the ability to
adopt healthy behaviors if given the proper guidance. The CHC interactions are geared toward
changing the behavior of the patient to foster changes in their health. Achievement of this goal
for T2D, or patients in a prediabetes state, is dependent on the patient changing their lifestyle to
include getting regular exercise, eating healthier foods, smoking cessation, or changing other
negative behaviors that are unique to a specific patient.
Grounded in coaching psychology, CHCs foster and promote the behavior change
processes that help produce desired health outcomes (Pettitt, 2013; Wayne & Ritvo, 2014). One
key element in reaching the desired change is the patient’s self-efficacy, or belief in their
capability to reach their goal. Promoting self-efficacy in patients is a major strategy in health
coaching to help patients develop the confidence needed to initiate change (Bandura, 1977). In
addition, it is important that health coaches develop positive experiences with their patients, as
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negative attitudes can have a major effect on a patient’s self-efficacy (Gonzalez et al., 2014). A
therapy designed to enhance self-efficacy increases patient involvement and activities that can
improve both their overall well-being and health outcomes (Wu et al., 2011).
Clinical health coaches often utilize the framework of the Transtheoretical Model (TTM),
a model that identifies stages of behavior change. Use of the TTM can help determine the
patient’s current position on change, as well as their readiness to make the behavior change.
Transtheoretical Model based interventions focused on physical activity, nutrition and behavior
change have shown reductions in weight, percent calories from fat and overall calorie intake, and
increases in exercise (Johnson et al., 2008; Riebe et al., 2003). The TTM consists of five stages
of change: precontemplation, contemplation, preparation, action, and maintenance. In the
precontemplation stage, persons are not intending to change in the near future. These individuals
may not be aware of their poor diet choice or the harmful effects of smoking and lack of
exercise. In the contemplation stage, persons are more aware of the pros and cons of change, and
have intentions of changing within 6 months. Persons in the preparation phase are ready to
change, usually within the next month. They have a plan of action and made accommodations to
move to the next phase. They may have researched exercise routines and/or gym options, or
researched healthy eating options. The action phase marks the first significant effort to change
their behavior. In the action phase, lifestyle modifications, such as quitting smoking, refraining
from buying high sugar/high fat foods, and beginning an exercise regimen, are started. Those in
the maintenance phase are trying to prevent a relapse back to the undesired behavior. These
individuals continue to eat healthy, exercise regularly, and avoid poor health choices. Movement
from phase-to-phase is different for each individual; however, those participating in a TTM are
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more likely to move to action and maintenance stages for self-monitoring of blood glucose and
healthy eating (H. Jones et al., 2003).
Adopting the TTM, CHCs often use motivational interviewing (MI) in coaching sessions.
Motivational interviewing is a coaching approach centered on the patient’s readiness to change,
and is defined as “client centered, directive method for enhancing intrinsic motivation to change
by exploring and resolving ambivalence” (Miller, 2002). Motivational interviewing assists the
CHC to determine how the CHC interaction session should be carried out (Marley, Carbonneau,
Lockner, Kibbe, & Trowbridge, 2011). Motivational interviewing has the potential to improve
patient self-efficacy, patient activation (the patient’s empowerment to work with their provider to
manage their health), and perceived health status (Linden, Butterworth, & Prochaska, 2010). In
addition to MI, CHCs are trained to provide empathy during their interaction with the patient.
Empathy is cognitive understanding of what the patient is feeling or going through and being
able to project this in a way that can foster assistance for the other individual (Hojat, Louis,
Maio, & Gonnella, 2016; Hojat, 2007). Empathy can create a bond and strengthen trust between
the patient and CHC (Hojat, Louis, Maio, & Gonnella, 2013). The use of MI during CHC
interactions can further foster empathy from the CHCs. When used during health coaching
sessions, a combination of MI and patient education session has shown to reduce BMI and waist
circumference, and increase physical activity compared to those receiving education alone (p<
0.001) (Barrett, Begg, O’Halloran, & Kingsley, 2018). Furthermore, in their 2007 study, Brug et
al. demonstrated that the use of MI to elicit empathy in patient centered coaching sessions results
in lower saturated fat intake compared to patients seen by non-MI based dietitians (Brug et al.,
2007).
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Health coaches have been used to improve the general health of patients as well as in the
treatment of patients with chronic conditions such as hypertension and diabetes. In a recent
study, Leahey and Wing investigated the impact of three different types of health coaches on
subjects in a weight loss program over six months. Subjects were all enrolled in a reduced
intensity behavioral weight loss treatment, with caloric intakes limited to 1200-1500 kcal daily.
They were expected to increase activity to 40 minutes each day for 5 days per week. This
program consisted of weekly meetings for the first six weeks, biweekly meetings (once every
two weeks) for the next six weeks, and then monthly meetings for the last three months of the
six-month program. Eligible participants were randomized into one of the three types of health
coaches: professional (n=14), peer (n=16), or mentor (n= 12). The study results demonstrated
that participants across all of the groups showed reduction in body weight; however, those who
received the professional health coach intervention had the greatest percentage of weight loss
(Leahey & Wing, 2013).
Apple et al. investigated the effects of different types of health coach interactions on
weight loss and the ability of participants to meet the goal of either 5% and/or 10% weight
reduction. Four hundred and fifteen obese patients were randomly assigned to one of three
groups: 1) a control group with self-directed weight loss management, 2) a remote intervention
group receiving weight loss support over the telephone, a study website, and email, and 3) an inperson intervention group receiving both group and individual weight loss management support.
After 24 months, both intervention groups showed significant weight loss vs. the control group
(p<0.001). There was no significant difference in weight loss or participant ability to meet
weight loss goals between the remote or in-person intervention groups (Appel et al., 2011). The
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study also provided evidence that CHC interactions can be impactful using technology, and that
face-to-face communication may not be necessary to influence patient behavior change.
Battista et al. investigated the effects of a 12-month dietitian-coached program on T1D
and T2D patients. In their study, participants were assigned to either a control group with only
endocrinologist guidance (n=50), or a treatment group receiving quarterly on-site diabetes selfmanagement education with annual endocrinologist follow-up (n=51). They reported that
repetitive dietitian guidance significantly reduced %HbA1c levels (0.6% reduction, p=0.04) vs
the control group (Battista et al., 2012).
Mobile technologies could help facilitate coaching by introducing a new method of
communication to aid in client/health coach interactions. The use of smartphones would allow
faster responses to client questions and encourage a consistent stream of communication between
the health coach and the client. In 2014, Wayne and Ritvo demonstrated that health coach
interaction conducted via smartphone technology could aid in the management of clients with
T2D. The goal of their study was to test a newly developed smartphone-assisted intervention to
improve behavioral management of T2D in an ethnically diverse, lower socioeconomic
population within an urban community health setting. A new smartphone application, the
Connected Health and Wellness Platform (CHWP) Health Coach App, was tested in a 24-week
intervention with reduction of %HbA1c levels as the primary outcome of interest. For the 19
individuals entered into their study, the overall mean reduction in HbA1c level was 0.28%. In 12
subjects who started the program with %HgbA1c values > 7%, the mean reduction was 0.43% (p
< 0.05) (Wayne & Ritvo, 2014).
Research into CHC interaction and improvement of health outcomes shows patient
benefit with CHC utilization. However, there is no published research on the effect of CHC
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interactions on early markers of insulin resistance and beta cell dysfunction, or research
concerning the number of interactions required to achieve these benefits. In a systematic review
of literature on health/wellness coaching and effects on various aspects of health, Wolever found
that of the 284 health/wellness coach studies identified, 148 did not specify the total number of
coaching sessions used (Wolever et al., 2013). Of the remaining 136, the authors did not
investigate the effects of varying numbers of sessions. In addition, only 185 of the 284 total
studies were empirical with systematic data collection. In the relevant articles reviewed, study
participants in the intervention group underwent structured initial coaching sessions, with several
studies investigating the effects of long-term coaching over several years. Variations in the
timeframe of coaching interventions were noticed in several studies in their review; however,
research specifically the effects of the number of coaching sessions on change in health
outcomes was not reported.
In their 2008 study, Bray et al. investigated the effects of a diabetes life coach on recently
diagnosed T1D and T2D patient health. Study participants were assigned a life coach for
guidance on exercise and diet lifestyle modification. Participants were deemed engaged,
participating in face-to-face and telephone interventions, or non-engaged. Life coach-patient
interactions were at least biannually, with the opportunity for unlimited access if necessary. They
found that individuals who were engaged were 50% more likely to meet ADA guidelines of
%HbA1c levels < 7.0%, with interventions improving adherence to diet and exercise routines,
and medication regimens ( p <0.001). The number of visits was not recorded, but could have
been a potential co-variate in their analysis (Bray, Turpin, Jungkind, & Heuser, 2008).
In their systematic review of the effect of telephone interventions on exercise and dietary
behavior change, Eakin et al. noted that factors associated with a positive outcome included
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programs that lasted between 6-12 months and those with 12 or more interactions during their
study (Eakin et al., 2007). Research describing the effects of differences in the number of CHC
interactions and changes in biomarkers of glucose homeostasis could provide evidence that
scheduling additional CHC interactions could improve the health outcomes of patients with or at
risk of developing diabetes. Therefore, additional research on the effectiveness of CHCs has the
potential to influence patients to pursue treatment routes that include CHC engagement.
Furthermore, the lack of research on the effects of CHC interactions on other markers of glucose
homeostasis such as 1,5-AG and markers of beta cell health such as proinsulin, insulin, and Cpeptide represents a gap in the knowledge of CHC capabilities. This study investigated if there is
a relationship between CHC interactions and changes in biomarkers of glucose homeostasis.
Finally, the study explored if the number of CHC interactions is related to those changes.
Chapter Summary
Chapter 2 reviewed disorders of glucose homeostasis, biomarkers of this process and of
diabetes and prediabetes, and reviewed the CHC profession. Chapter 2 summarized the impact of
CHC interactions on changes in personal behavior and lifestyle modifications. The review of
available literature demonstrates the ability of CHC interaction to improve patient health and its
importance to health care. Literature on CHC interactions and changes in diabetes-related
markers is not limited. However, research on the effect of the number of CHC interactions on the
levels of specific biomarkers is lacking. Furthermore, knowledge of CHC interactions and their
effect on additional markers of glucose homeostasis and beta cell health is absent.
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Chapter 3: Methodology

Overview
Chapter 3 discusses details of the research design, subject database creation, subject
selection, the research setting, and study variables. The databases used to gather patient results
and CHC interaction are described, including data extraction, assessment of validity, and
database management. Statistical analyses used to evaluate each Specific Aim are discussed.
Problem Statement
Many patients find it difficult to change their lifestyle based on health care provider
recommendations, despite the understanding that it is needed to improve their overall health.
Less than 20 % of adult diabetics comply with provider prescribed medications and lifestyle
modifications (Funnell, 2006; Gonzalez et al., 2014; Willard-Grace et al., 2013). This suggests
that doctor-patient interaction is not sufficient in implementing lifestyle changes. Some studies
demonstrate that CHC interactions may help facilitate and improve adherence to these lifestyle
changes, improving BMI and % HbA1c, a marker of glucose homeostasis (Haas et al., 2012;
Leahey & Wing, 2013; Liddy et al., 2014; Wayne & Ritvo, 2014) . However, there are no
published studies relating the number of CHC interactions to the magnitude of change in specific
markers. There is also no published research on how CHC interactions affect changes in other
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markers of glucose hemostasis such as 1,5-AG, or markers of beta cell function such as
proinsulin, insulin, and C-peptide.
Research Question, Specific Aims, and Hypotheses
The research question for this study is: is there a relationship between the changes in
patients’ biomarkers of glucose homeostasis and beta cell function and utilization of CHCs?
Specific Aim 1: Determine if there are statistically significant differences between
patients who do or do not participate in CHC interactions in their changes in 1) blood
glucose concentration, 2) %HbA1c, 3) blood 1,5-anhydroglucitol concentration (1,5-AG),
4) blood insulin concentration, 5) blood C-peptide concentration, 6) blood proinsulin
concentration, and 7) body mass index (BMI).
To accomplish this aim, the following hypothesis was tested:
There is no significant difference in the changes in blood glucose, %HbA1c, 1,5-AG,
insulin, C-peptide, proinsulin or BMI between patients who interacted with CHCs and
those who did not.
This was tested by comparing the difference between initial and follow-up biomarker results, 1014 months from initial testing, for two groups, 1) those who participated in CHC interactions,
and 2) those who did not. Changes in biomarker values were calculated for each marker in both
the CHC and non-CHC groups and compared statistically.
Specific Aim 2: Determine if statistically significant differences exist in the change in
glucose, HabA1c, and BMI health scores between subjects who did and those who did
not interact with CHCs.
To accomplish this aim, the following hypotheses will be tested:
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There is no significant difference in the change in health scores for glucose, %HabA1c,
and BMI for patients who had CHC interactions and those who did not.
Aim 2 was accomplished by first assigning a “health score” to the initial and follow-up
biomarker results. Health score were based upon ADA recommended cutoffs for normal,
prediabetic, and diabetic values for glucose and HbA1c, and BMI guidelines for normal,
overweight, and obese individuals. Normal values for glucose and %HbA1c and a normal BMI
were given a score of 0. Individuals in a pre-diabetic state based on glucose and %HbA1c results,
and those with BMIs in the overweight category were assigned a score of 1. Those in the diabetic
and obese classifications were assigned a value of 2. Changes in health score were evaluated by
subtracting the follow-up score from the initial score and compared between the treatment and
control group.
Specific Aim 3 Determine the relationship between the number of CHC interactions and the
magnitude of the change in 1) blood glucose concentrations, 2) % HbA1c, 3) blood 1,5anhydroglucitol (1,5-AG) concentrations, 4)blood insulin concentrations, 5) blood C-peptide
concentrations, 6) blood proinsulin concentrations and 7) body mass index (BMI).
To accomplish this aim, the following hypotheses will be tested:
There is no relationship between the number of CHC interactions and the change in blood
glucose concentration, %HbA1c, 1,5-AG, insulin, C-peptide, proinsulin, or BMI.
Specific Aim 3 will be accomplished by linear regression of the magnitude of change in patient’s
marker results versus the number of CHC interactions. Additionally, a one-way t-test was used to
compare the mean change of those subjects who utilized CHC interactions.
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Research Design
The current study utilized a retrospective non-experimental study design to investigate
the relationship between changes in patients’ biomarker results and CHC interactions (Polit,
2008). The retrospective design allows for the collection of data across varying ages, sex, and
patient BMI over a span of four years, which would not be practical if a true experimental design
were utilized. Repeated measures were used to identify the changes in marker results from the
subjects’ initial blood draw to their follow-up blood draw 12+2 months after their initial draw.
Sampling Strategy
Preliminary research identified over 200,000 patients that had initial test results and at
least one set of results 10 to14 months later. The study sample included all of the patients who
did not meet the exclusion criteria:


Patients under the age of 18 years old.



Patients over the age of 89 years old



Patients missing age, sex, and BMI demographics

Population and Sample
The target population was all persons seen by a health care provider that had laboratory
testing performed at the Richmond, VA based laboratories, Health Diagnostics Laboratory and
True Health. This population included patients from across the continental United States. The
sample for the study consisted of patients with follow-up testing 12+2 months after initial testing
between April 2, 2012 and July 15, 2016. A data use agreement between Virginia
Commonwealth University (VCU) and True Health was signed, allowing research collaboration.
In addition, an approved VCU IRB (IRB HM20013795) qualified for exemption according to 45
CFR 46.101(b), Category 4 prior to data collection. In 2012, the laboratory began offering
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providers a menu of tests specific to diabetes, glucose homeostasis, and pancreatic health. This
offered providers a tool to screen patients for their risk of developing diabetes and to help
monitor patients already diagnosed with diabetes or insulin resistance.
Handling of Protected Health Information
For this study, only deidentified patient information was provided to the principle
investigator (PI). The information technology (IT) team removed patient identifiers such as
name, date of service, medical record number, and sample ID, and assigned a study number to
each subject, prior to allowing the PI access to the data. Only the subjects’ biomarker test results,
age, gender, and BMI were included in the final Excel worksheet used for the data analysis. A
data use agreement between True Health and VCU along with VCU IRB approval (IRB
HM20013795) ensure patients are protected and permission granted to use deidentified patient
data.
Variables
Disease marker results were from previously tested subject samples. The same dependent
variables were utilized for both Specific Aim 1 and 3: changes in the results for glucose,
%HbA1c, 1,5-AG, proinsulin, insulin, and C-peptide, and BMI over a 10-14-month period. The
units of measurement for all dependent variables are given in Table 3.
Table 3: Units of Measure
Test
Glucose
Hemoglobin A1c
1,5-Anhydroglucitol
Insulin
C-Peptide
Proinsulin
BMI

Units of Measurement of Change
mg/dL
%
µg/mL
μU/mL
ng/mL
pmol/L
Weight (Kg)/(height (m))2
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Specific Aim 1 has one independent variable, CHC interactions or no CHC interactions.
The independent variable for Specific Aim 3 was the number of CHC interactions over the 10-14
month interval for those subject in the study. Specific Aim 2 had the same subjects as Specific
Aim 1 for glucose, HbA1c, and BMI. The IV was also the same, but the DVs were the changes
in health score for glucose, HbA1c, and BMI. Specific Aim 2 health scores are described in
Table 4.
Table 4: Health Score Variable Table

Test
Glucose
Hemoglobin A1c
BMI

Initial Testing
Health score
Health score
(Category)
Health score
(Category)
Health score
(Category)

Follow-up Testing Mean Change in
Health score
Health score
Health score
Absolute
(Category)
health score change
Health score
Absolute
(Category)
health score change
Health score
Absolute
(Category)
health score change

Patient demographics of age, sex, initial BMI, and initial marker values were used as
covariates (CV) in the statistical analysis for all three Aims. The CHCs used in this study were
registered dietitians, exercise specialist, or registered nurses. These CHCs may have prior
certifications in health or wellness coaching; however, no certifications in were required for
employment. All CHCs did complete an initial training, including the completion several online
based training specific to behavior change, as well as annual competency assessments. The study
variables described above are listed in Table 5.
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Table 5: Study Independent and Dependent Variables
Variable
CHC (Y/N)

Number of CHC
interactions

Level of
Measurement
Dichotomous

Interval

Change in glucose

Ratio

Change in %
hemoglobin A1c
Change in 1,5Anhydroglucitol

Ratio

Change in insulin

Ratio

Change in Cpeptide
Change in
proinsulin
Change in BMI

Ratio

Change in glucose
health score

Ratio

Change in HbA1c
health score

Ratio

Change in in BMI
health score

Ratio

Ratio

Ratio
Ratio

Definition of Variable
Exposure to CHC.
Transferred to 0 and 1 for
statistical analysis. 1
defines CHC visits, 0
defines no CHC visits
If utilized CHC, the
number of interactions
during study timeframe
Difference between initial
and follow-up glucose
Difference between initial
and follow-up %HgbA1c
Difference between initial
and follow-up 1,5anhydroglucitol
Difference between initial
and follow-up
Difference between initial
and follow-up proinsulin
Difference between initial
and follow-up C-peptide
Difference between initial
and follow-up BMI
Difference between initial
and follow-up Glucose
health score
Difference between initial
and follow-up HbA1c
health score
Difference between initial
and follow-up BMI health
score

By Aim, IV, DV,
or CV
Aim 1-IV
Aim 2-IV

Aim 3-IV

Aim 1-DV
Aim 3-DV
Aim 1-DV
Aim 3-DV
Aim 1-DV
Aim 3-DV
Aim 1-DV
Aim 3-DV
Aim 1-DV
Aim 3-DV
Aim 1-DV
Aim 3-DV
Aim 1-DV
Aim 3-DV
Aim 2-DV

Aim 2-DV

Aim 2-DV

CV= covariate, DV = dependent variable, IV = independent variable

.
As previously mentioned, the patient demographics of age, sex, and initial BMI were
collected and used as covariables in the statistical analysis of the data. Increases of age as well
as BMI have been highly correlated with incidences of diabetes. (American Diabetes
Association, 2013); (Centers for Disease Control and Prevention, 2017). Using these as
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covariates helped identify the effects of age, sex, and BMI on potential change in biomarker
values. For evaluating change in BMI, only the subject’s age and sex were included as covariates
since changes in BMI is the dependent variable. To evaluate the possible propensity for a subject
to participate in CHC interactions, the relationship between initial biomarker value and changes
in biomarker values was investigated using ANCOVA. The study CVs are listed in Table 6.
Table 6: Study Covariates
Variable
Subject ID
Sex

Age at initial testing

Level of
Measurement
Nominal
Dichotomous

Interval

Definition of Variable
Assigned study number
Transformed to 0 and 1
for statistical analysis. 1
defines male, 0 defines
female
Time in years

Initial BMI

Ratio

Initial glucose

Ratio

BMI at initial blood Draw
is used as part of the DV,
change in BMI. BMI
could be a CV for all
biomarkers.
Used as a CV

Initial HbA1c

Ratio

Used as a CV

Initial 1,5-AG

Ratio

Used as a CV

Initial insulin

Ratio

Used as a CV

Initial C-peptide

Ratio

Used as a CV

Initial proinsulin

Ratio

Used as a CV
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By Aim, IV, DV,
or CV
Aim 1-CV
Aim 2-CV
Aim 3-CV
Aim 1-CV
Aim 2-CV
Aim 3-CV
Aim 1-CV/DV
Aim 2-CV/DV
Aim 3-CV/DV

Aim 1-CV
Aim 2-CV
Aim 3-CV
Aim 1-CV
Aim 2-CV
Aim 3-CV
Aim 1-CV
Aim 3-CV
Aim 1-CV
Aim 3-CV
Aim 1-CV
Aim 3-CV
Aim 1-CV
Aim 3-CV

Marker Testing Methods
Glucose. Glucose was measured using the Beckman Coulter 5800 automated chemistry
analyzer. This analyzer utilizes the hexokinase method for glucose measurement (Stein, 1965).
The Beckman Coulter 5800 has an analytical measurable range (AMR) between 10-800 mg/dL
and a Clinical reportable range (CRR) between 10-2400 mg/dL with auto dilution. To evaluate
assay performance, daily quality control (QC) results were averaged amongst all instruments
used for patient testing over the lifetime of a single lot. Based upon quality control data for four
instruments from January 1, 2018 and June 20, 2018, the coefficient of variation for this assay
was 1.08% at a concentration of 59.57 mg/dL, and 1.74% at a concentration of 362.85 mg/dL.
The most recent calibrator lot verification, performed in November 2017, indicated a 0% bias
between the previous lot and the new lot.
HbA1c. Prior to March 2015, the Richmond based laboratory utilized the BIO-RAD
VARIANT II Turbo for measuring %HgbA1c. This method utilizes ion exchange high-pressure
liquid chromatography (HPLC) (Jones 1979). In 2014, the laboratory changed to the Premier
Hb9210™ HgbA1c Analyzer, manufactured by Trinity Biotech, for %HgbA1c measurement,
which utilizes boronate affinity HPLC (Fairbanks & Zimmerman 1983); (Millia 1981). The
method comparison between the two showed a slight positive bias in the Trinity assay (Y),
Y=1.0553x-0.1088, R2 = 0.9873.
The daily QC results were averaged amongst all instruments over the lifetime of a single
lot to evaluate assay performance. The Trinity Premier quality control data for seven
instruments used of patient testing from October 2, 2017 to June 20, 2018 the coefficient of
variation for this assay was 1.23% at a concentration of 6.04% HgbA1c, and 1.61% at a
concentration of 9.70% HgbA1c. The most recent calibrator lot verification, performed in May
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2018, indicated a 1 % bias between the previous lot and the new lot. The BioRad Turbo Variant
II quality control data for six instruments from December 11, 2013 to March 22, 2014, had a
coefficient of variation of 2.36% at a concentration of 5.36% HgbA1c, and 1.61% at a
concentration of 9.70% HgbA1c.
1,5-AG. Serum 1,5-AG was measured on the Beckman Coulter AU 5800 platform, with
a two-step enzymatic assay and reagents produced by Glycomark (Yamanouchi 1996). Assay
AMR is 1.0-100 µg/mL. The daily QC results were averaged amongst all instruments used for
patient testing over the lifetime of a single lot. The coefficient of variation for this assay was
3.9% at a concentration of 5.47 µg/mL, and 2.56% at a concentration of 14.51 µg/mL for a single
lot of QC used on seven instruments between December 19, 2017 to April 2, 2018. The most
recent calibrator lot verification, performed in July 2017, indicated a -2% bias between the
previous lot and the new lot.
Insulin. Insulin was measured on the Roche EMODTM electro-chemiluminescence
testing platform. The EMODTM Elecsys insulin assay utilizes the sandwich immunoassay
principle utilizing monoclonal antibodies specific for insulin (Sapin et al., 2001). The AMR is 11000 µU/mL. Daily QC results were averaged amongst all instruments over the lifetime of a
single lot. Based upon quality control data for six instruments totaling 12 measuring cells
between April 25, 2018 and June 20, 2018, the coefficient of variation for this assay was 2.51%
at a concentration of 25.39 µU/mL, and 2.29% at a concentration of 77.08 µU/mL. The most
recent calibrator lot verification, performed in August 2017, indicated a -2% bias between the
previous lot and the new lot.
C-peptide. C-peptide was measured on the Roche EMODTM electro-chemiluminescence
testing platform. The Roche EMOD TM assay utilizes the sandwich principle, and uses two
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monoclonal antibodies specific for C-peptide (Kao, Talyor, & Heser 1992). The AMR is 0.3 – 40
ng/mL. The daily QC results were averaged amongst all instruments over the lifetime of a single
lot. The coefficient of variation for this assay was 2.02% at a concentration of 1.94 ng/mL, and
2.46% at a concentration of 9.65 ng/mL for four instruments, totaling eight measuring cells for a
single lot of QC between February 20, 2018 and June 20, 2018. The overall mean bias for two
calibrator lot verifications, performed in 2018, was 0.0%.
Proinsulin. Proinsulin was measured on the Dynex DSXTM testing platform, utilizing an
ELISA kit from MercodiaTM. The proinsulin assay is a solid phase assay based on the sandwich
immunoassay principle, employing two monoclonal antibodies against separate antigenic
determinants on the proinsulin molecule (Kjems et al, 1993). The AMR is 2-150 pmol/mL, with
a CRR of 2-1500 with auto dilution. To evaluate assay performance, daily QC results were
averaged amongst all plate runs over the lifetime of a single lot. Based upon quality control data
between May 1, 2018 and June 20, 2018, the coefficient of variation for this assay was 3.92% at
a concentration of 9.11pmoL/L, and 6.13% at a concentration of 31.23 pmoL/L. The most recent
lot verification, performed in November 2017, indicated a -2 % bias between the previous lot and
the new lot.
From April 2012 to July 2016, all of the assays used to measure the biomarkers included
in this study underwent changes in reagent and calibration lots that could have potentially led to
differences in biomarker results from the initial measurement to the follow-up measurement. The
Richmond based laboratory utilized the following protocol to minimize shifts in patient results
due to lot changes:


For reagent lot changes, 10 patients that ranged from the low-end to the high-end
of the assay AMR, along with QC, were run using the current lot of reagent, and
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again using the new lot of reagent. A percent bias of less than 10% was required
for the new lot to be accepted.


For calibrator lot changes, 10 patients that ranged from the low-end to the highend of the assay AMR, along with QC, were run using the current calibration
curve , and again using the new calibration curve. A percent bias of less than 10%
was required for the new lot to be accepted.

BMI. Body mass index is calculated as the patient’s mass divided by the square of their
height in meters =

𝑀𝑎𝑠𝑠 (𝑘𝑔)
(𝐻𝑒𝑖𝑔ℎ𝑡 (𝑚))2

. Height and weight, if available, were collected at the time of

blood draw. Body mass index can be categorized as underweight, normal, overweight, and obese,
with obesity subdivided into three classes. The BMI classifications for the current study are
displayed in Table 7. For the purpose of this study, health scores were assigned solely according
to the categories of normal, overweight, and obese.
Table 7: Patient Classification by BMI
BMI category
Underweight
Normal
Overweight
Obesity Class 1
Obesity class 2
Extreme Obesity Class 3

BMI (kg/m2)

Study Classification

< 18.5
18.5 – 24.9
25.0 – 29.9
30.0 – 34.9
35.0 – 39.9
≥ 40

NA
Normal
Overweight
Obese
Obese
Obese

Adopted from (Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in
adults : The evidence report 1998)

Research Setting
Laboratory testing was completed at either Health Diagnostics Laboratory or True Health
Diagnostics, in Richmond, Virginia. The patient population was dispersed throughout the
continental United States. Most, but not all specimens, were collected at a physician’s office or
at other draw sites by a phlebotomist. All samples were sent to Richmond, Virginia for testing
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and usually arrived within 24 hours of the venipuncture. All samples were shipped with ice packs
to ensure the optimal temperatures were maintained during sample transportation, with
temperature verification if samples were suspected of being out of optimal refrigeration
temperature range of 2-8°C. The laboratory Pre-Analytics Department received and accessioned
all serum separator tubes (SST) and whole blood Ethylenediaminetetraacetic acid (EDTA) tubes.
Samples received unspun or outside the optimum temperature range were flagged and affected
tests were not tested.
Patient-CHC interactions were conducted in in a variety of locations. For face-to-face
interactions, the CHC met with the patient either at a physician’s office or a wellness location, an
office provided to CHCs and other health practitioners. Patient-CHC interactions could have
also occurred over the phone. In either setting, the CHCs were instructed to follow the same
CHC visit protocol in accordance with their training. In addition, CHC interactions could vary in
length of time or topics discussed based on patient conditions. There was no data recorded on the
length of the visit or topics discussed during the CHC interaction.
Data collection and analysis took place at True Health Diagnostics. Senior IT analysts
wrote the code that allowed a search of the LIS and IMS databases, and assisted with sorting and
refining data once extracted.
Data Collection
Data collection was a two-step process. First, a query of the LIS identified potential study
subjects. The IT team at the laboratory identified patients who had an initial blood draw after
April 1, 2012, and that had a follow-up blood draw 10 to 14 months after their initial blood draw,
up to July 15, 2016. Once potential study subjects were selected from the LIS query, a search of
the CHC information management system (IMS) for the same subjects provided the number and
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date of the subjects’ CHC interactions, if any. The format of each of the data elements that were
extracted from each of the two databases are listed in Table 8.
Table 8: Subject Data Elements Extracted from Harvest LIS and Health Coach IMS
Data Element
Patient identification number
Sample ID at initial draw
Date of initial draw
Age at initial draw
BMI at initial draw
Sample ID at follow up draw
Date of follow up draw
Age at follow up draw
BMI at follow up draw
CHC interactions During Study
Sex

Format
XXXXXXX
YYMMDDXXXXX
MM/DD/YYYY
Digit-Continuous
Digit-Continuous
YYMMDDXXXXX
MM/DD/YYYY
Digit-Continuous
Digit-Continuous
0 for no CHC or 1for CHC
M/F
0 for non-fasting, 1 for fasting, or
2 for not indicated
Digit-Continuous
0 for non-fasting, 1 for fasting, or
2 for not indicated
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous

Fasting Status at initial draw
Fasting Time at initial draw
Fasting status at follow up draw
Fasting time at follow up draw
Glucose at initial draw
%HgbA1c at initial draw
Insulin at initial draw
Proinsulin at initial draw
C-peptide at initial draw
1,5-anhydroglucitol at Initial Draw
Glucose at follow up draw
%HgbA1c at follow up draw
Insulin at follow up draw
Proinsulin at follow up draw
C-peptide at follow up draw
1,5-anhydroglucitol at follow up draw

The data from the LIS and IMS were merged into a single Microsoft Excel file. After
verification of the data, the IT team provided the PI with a deidentified file. The final
deidentified study components are listed in Table 9.
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Table 9: Deidentified Study Dataset
Data Element
Subject Number
Age at Initial Draw
Age at Follow-up Draw
Sex
Fasting at Initial
Fasting Time at Initial Draw
Fasting at Follow-up Draw
Fasting Time at Follow-up Draw
Number of CHC Visits During the Study
Timeframe
Number of CHC interactions During Study
BMI at Initial Draw
BMI at Follow-up Draw
Insulin at Initial Draw
Insulin at follow up draw
Glucose at Initial Draw
Glucose at follow up draw
Hemoglobin A1c at Initial up draw
Hemoglobin A1c at follow up draw
C-peptide at Initial up draw
C-peptide at follow up draw
Proinsulin at Initial up draw
Proinsulin at Follow-up draw
1,5-AG at Initial up draw
1,5-AG at follow up draw

Format
Digit
Digit
Digit
M/F
0, 1, or 2
Digit
0, 1, or 2
Digit
0 or 1
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous
Digit-Continuous

Validity and Reliability
Specimen integrity, accuracy of specimen testing and verification of data collection, were
essential to ensure the results of the current study were valid and reportable. Improperly
collected, transported, or stored sample could have varying effects on the quality of results
generated from laboratory instrumentation. Preanalytical component of laboratory quality control
included a check of specimen integrity and proper labeling prior to testing. Blood specimen
integrity, i.e. proper tube labeling, shipping temperature of 2-8°C (specimens were acceptable if
shipped with a cold pack and/or temperature was verified by infrared thermometer if temperature
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was questioned), signs of hemolysis, clotted or specimens partially spun samples, was checked
upon arrival to the laboratory that performed the analysis. The Pre-Analytics team reviewed all
specimens for proper shipping conditions. The date and time of collection was also recorded by
the Pre-Analytics team, but not included in the study dataset.
To ensure accuracy of specimen testing, the laboratory adheres to analytical quality
control measures. Daily, weekly, monthly, and annual maintenance was performed and
documented for all instruments and equipment used in the preanalytical and analytical phases of
testing, according to manufacturer’s guidelines and standards set forth by the College of
American Pathologists (CAP). Calibration and QC of all testing methods were performed in
accordance with manufacturers’ guidelines or laboratory operating procedure, whichever was
more stringent. New lots of reagent and calibrator were verified according to the laboratory’s
standard operating procedures, which require that 10 patient specimens that span the AMR along
with quality controls for the analyte were measured with both the current and new lot of reagents
or calibrator. The % bias slope between the two lots must be less than ±10% to be acceptable.
Quality control measures were also taken in the post analytical phase of data collection.
The use of two databases allowed for the collection and merging of data while reducing the
potential of human error associated with transcription. Results were automatically transferred
from the LIS and MS to the Excel file without human manipulation. The IT team checked 100
random subjects from the combined Excel database file and compared their name, initial and
follow-up biomarker testing results, and demographics to those in the LIS and IMS to ensure
they match. Once the data set was established, The IT team de-identified the subjects by
replacing patient name and sample number with a new unique study number that was unrelated
to the laboratory patient identification system.
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Polit and Beck (2008) define internal validity as the ability of the study to measure a true
effect rather than another external factor (Polit, 2008). This study was subject to threats of
internal validity concerning the laboratory testing and CHC interactions. Threats to internal
validity concerning the laboratory instrumentation were reduced by limiting testing platform
variation by following the analytical standards described above required by the laboratory and
accrediting agencies. Concerning CHC interactions, threats to internal validity were reduced by
ensuring CHCs followed a structured protocol for behavior change during interactions. Before
CHCs were allowed to interact with clients, all CHCs were required to participate in company
mandated training courses. The goal of their training was to standardize the approach of the
consultation while adapting the best counseling method dependent on the patient’s readiness and
ability to change the behavior of interest. However, CHC interactions may vary from one patient
to another, as well as from health coach to health coach.
Sample Size and Statistical Power
Sample size requirements were dependent on effect size, power, significance, and the
number of predictors. A post-hoc sample size calculation was performed with a confidence of
80% against Type II errors and a confidence of 95% against Type I errors. Effects size, the
difference between two groups, aids in the statistical explanation of the effectiveness of a
particular intervention.
The study utilized Cohen’s d to generate estimates of effect size for all biomarkers and
BMI. Cohen’s d=

𝐺𝑟𝑜𝑢𝑝 1 𝑚𝑒𝑎𝑛−𝐺𝑟𝑜𝑢𝑝 2 𝑚𝑒𝑎𝑛
𝐺𝑟𝑜𝑢𝑝𝑠 𝑐𝑜𝑚𝑚𝑜𝑛 𝑆𝐷

. A Cohen’s of 0.2 is considered a small effect size, a

Cohen’s d of 0.5 is considered a medium effects size, and a Cohen’s d of 0.8 is considered a
large effect size (J. Cohen, 1988). To assess effect size of CHC interactions and change in the
study biomarkers and BMI, the effects size was calculated post hoc using means and SDs
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gathered during data collection and calculated from SPSS frequency data analysis. Soper’s
online calculator for apriori estimates for a multiple regression analysis was used to determine
sample size requirements, using a power 0.8, probability level of 0.05, the effects size for each
DV, and up to five predictors dependent on individual model CVs where significant (Soper,
2018).
Data Cleaning
Data from both the laboratory LIS and the CHC IMS were merged into a single Microsoft
Excel file. The Excel data set was examined for accuracy by the IT team. One hundred random
subjects from the unaltered data set were checked against the LIS and IMS for biomarker,
demographics, and CHC interaction data. The following were removed from the Excel
spreadsheet prior to loading into SPSS:


Patients that did not have both an initial and follow-up result for the disease marker
being analyzed



Non-fasting initial and final draw results for glucose, proinsulin, insulin, or Cpeptide.

After the data set was reviewed in Excel, the data set was imported into SPSS v24 for data
analysis (IBM Corp. 2016).
Randomization was required for the selection of the control groups (non-CHC groups) to
test the hypotheses for Specific Aims 1and 2. Subjects from the non-CHC group were randomly
selected to match the approximate number of subjects in the CHC group for each biomarker,
with the exception of 1,5-AG. For 1,5-AG, the number of subjects in the CHC group (n = 142)
was > 10% of the non-CHC group (n = 25). Therefore, randomization was not required. The
number of subjects in the CHC group was divided into the number of subjects in the non-CHC

57

group to calculate the percent of subjects needed to for random selection. Once the percentage
was calculated, SPSS was used to randomly select the corresponding number of subjects from
the non-CHC group. The number of subjects used to test each hypothesis is shown in Table 10.
Table 10: Non-CHC Random Selection

Test

Glucose
Hemoglobin
A1c
1,5-AG
Insulin
C-Peptide
Proinsulin
BMI

CHC
and
nonCHC
Sample

CHC
Subjects

NonCHC
Subjects

% of nonCHC
Subjects
Selected for
Analysis

Calculated
non-CHC
Sample

Final
Sample
Size for
Analysis

15,803

969

14,834

6.5

975

1944

37,594

1,357

36,597

3.7

1328

2685

142
15,375
3739
2303
88747

25
1031
407
277
4029

117
14,344
3332
2026
84718

21.4
7.1
12.2
13.7
4.8

NA
922
425
257
4043

NA
2023
832
534
7854

To ensure the randomly selected sample was not statistically different from the total nonCHC population, ANOVA was performed on the age, sex, BMI, the initial value for each marker
to answer the question, was whether there was a difference in each of the variables between the
group randomly sampled from the non-CHC data set and the complete non-CHC data set? The
results from the ANOVA, as shown in Table 11, demonstrate that there was no statistically
significant difference in age, sex, initial BMI or initial marker result between the entire non-CHC
sample and the subjects randomly selected for inclusion in the statistical analysis.
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Table 11: Non-CHC Random Selection ANOVA
Test
Glucose
Hemoglobin
A1c
1,5-AG
Insulin
C-Peptide
Proinsulin
BMI

Age
p value

Sex
p value

Initial BMI
p value

0.306
0.378

0.142
0.444

0.464
0.563

Initial
Marker
p value
0.084
0.160

NA
0.365
0.651
0.717
0.370

NA
0.194
0.372
0.858
0.795

NA
0.956
0.916
0.870
0.613

NA
0.361
0.982
0.366
0.711

Missing data was not a threat to statistical validity as all missing biomarker data were
eliminated prior to loading the data set into SPSS. Descriptive statistics such as, means and
maximum and minimum values, for age, sex, initial BMI, and mean change in biomarker along
with their frequency distributions generated were generated in SPSS prior to data analysis.
Univariate outliers, or outliers within a single variable, were identified by analyzing
descriptive statistics and standardized z scores. The standardized score, or z score is the number
of standard deviations (SD) a particular value is from the mean of all values (Tabachnick &
Fidell, 2007). To reduce the effect of BMI univariate outliers on the statistical analyses, all initial
BMI values were converted to a standardized z score to identify potential outliers. Eligible
subjects from all six biomarker groups were entered into a single SPSS file. Descriptive analysis
performed in SPSS was able to generate a z score of each initial BMI to confirm with 99.9%
confidence that the cases in the BMI dataset are part of the population represented by the study
samples (Tabachnick & Fidell, 2007). Normalization of all subjects’ initial BMI was calculated
in SPSS to generate a standardized z score. BMI outliers were defined as a BMI z score of < -3.3
or > 3.3. Subjects with an initial BMI >52.26 were eliminated as having a z score > 3.3. None of
the initial BMI values had a BMI z score of < -3.3. However, The Diagnostic and Statistical
59

Manual of Mental Health Disorders (DSM-5), derived from World Health Organization
categories for thinness in adults, classifies BMI between 24 and 17 as mild anorexia, BMI
between 16.0-16.99 as moderate anorexia, BMI between 15.0-15.99 as sever anorexia, and BMI
< 15 as extreme anorexia (American Psychiatric Association, 2013). Subjects with BMIs <15
were eliminated as extreme values.
To identify univariate outliers, or extreme values for a single variable, the change in each
marker, with the exception of HbA1c, and BMI were converted to standardized z score in SPSS.
Markers with z scores < -3.3 and > 3.3 were eliminated as univariate outliers. For %HbA1c,
Tukey’s extreme values were used to eliminate univariate outliers related to difference in initial
and final HbA1c values. Tukey’s extreme values were chosen as opposed to z score distribution
due to the large number of cases that would have been eliminated if z score distributions were
used (Tukey, 1977). A change in %HbA1c > 9% was determined to be an outlier if z score
distributions were used, this was not such an abnormal value. In a 2015 study of %HbA1c
values and the risk of chronic obstructive pulmonary disease in patients with T2D, Li et al.
classified patients with HbA1c values > 10% as high, with 9,390 of their 45,753 subjects in that
category (Li et al, 2015).
Multivariate outliers, or a combination of extreme values, were identified by
Mahalanobis distance test (Mahalanobis, 1936). This test generates a score for each subject
based upon the combination of values of all variables and compares the score to the centroid for
all other subjects. The cutoff for MD with 6 degrees of freedom is 22.46 and 20.52 for 5 degrees
of freedom (Pearson and Hartly, 1958). Cases with MD greater than the cutoff were eliminated.
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Biomarker minimum and maximum values were compared to the clinical reportable
range (CRR) for their respective methods in the excel file prior to loading into SPSS. Values
outside their CRR (Table 12) were identified and deleted.
Table 12: AMR and CRR
Test
Glucose mg/dL
Hemoglobin A1c %
1,5-Anhydroglucitol
Insulin uU/mL
C-Peptide
Proinsulin

AMR

Dilution

CRR

10-800
3.8-18.5
1.0-110
1-1000
0.3-40.0
2.0-150

X3
NA
NA
NA
NA
X10

10-2400
3.8-18.5
1.0-110
1-1000
0.3-40.0
2-1500

Data Analysis
The goal of Specific Aim 1 was to determine if there are differences in the changes in
markers between patients who interacted with a CHC and those who did not. The change for
each marker for each case was calculated. The mean change for each marker for all subjects in
each group was then calculated, along with the variance in marker change within each group.
The change for each marker was compared between the two groups. Patient demographics of
age, sex, and initial BMI were used as covariates in the analysis of change in marker results and
included in the final statistical model if significant. For evaluating the relationship between CHC
interactions and changes in BMI, patient demographics of sex and age were used as covariates.
To evaluate the possibility that the propensity for a subject to seek CHC interactions might
influence the change in marker results, the relationship between initial biomarker values and the
change in biomarker values was investigated. A structural model was developed using the
general linear model (GLM) procedure in SPSS. For each marker change, CHC interaction and
all CVs were proposed as predictors. The GLM entered each variable using stepwise regression
and returned one or more models that were statistically significant (p<0.05) on their own and
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statistically significantly different from the prior (reduced) model. Estimates of the magnitude of
the correlation and statistical significance (P<0.05) of marker differences and exposure to CHC
interactions were provided for each model returned by GLM. For those markers in which a
significant relationship was found, initial biomarker values were used as covariates in the final
analysis. For each model returned by GLM, an ANOVA table provided sums of squares, an F
statistic, degrees of freedom for the model, a p value and an eta squared statistic. The final
model for each analysis included CHC interaction and any CVs that were statistically significant
(p<0.05). Standardized beta weights for each significant predictor in each model, and a t test for
each beta and zero-order correlations determined the effect size for each of the biomarkers or
how much variance is shared with the independent variable. The final model output stated if the
means between the two groups were statistically significantly different, as well as if the use of
CHC explained a statistically significant amount of that difference. A p value less than 0.05
indicated a statistically significant difference between groups, as well as a relationship between
CHC interaction and change in biomarker and BMI values.
The goal of Specific Aim 2 was to evaluate the change in glucose, %HgbA1c, and BMI
health scores. For this specific aim, the general construct of diabetic health was measured by
transformation of initial and final glucose, %HgbA1c, and BMI results into health scores. The
criteria for the assignment of health scores is listed in Table 13. Interaction with a CHC or no
interaction with a CHC was the IV. The change in health score was a separate DV. Interaction or
no interaction with a CHC was the IV, and initial marker values, if significant, along with age,
sex, initial BMI, and effects of the CHC interaction, were inserted step-wise as covariates into a
linear regression to attain estimates of the interactions. A p value less than 0.05 indicated a
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statistically significant difference between groups, as well as a relationship between CHC
interaction and change in biomarker and BMI health scores.
Table 13: Disease Marker Health scores
Health Score
Test
Glucose (mg/dL)
Hemoglobin A1c (%)
BMI

0
≤ 99
≤ 5.6
18.5-24.9

1
100-125
5.7-6.4
25.0-29.9

2
>125
≥ 6.5
> 29.9

For Specific Aim 3, the SPSS GLM procedure was again used to perform an ANCOVA
to provide relevant statistical evidence relating the number of CHC interactions to change in
mean marker values, using the number of CHC visits as the IV. As for Specific Aim 1, marker
differences were used as the DVs, each analyzed separately. Covariates were initial marker
values, age, sex, and initial BMI. Patients who did not interact with a CHC were not included in
this analysis. Linear regression was used to attain estimates of the relationship between the
number of CHC interactions and the changes in biomarker results. As with Aim 1, p values less
than 0.05 indicates a significant relationship between the number of CHC visits and marker
differences. A one way paired t-test was conducted to investigate the mean marker change
between the number of CHC interactions defined as one, two, three, and four or more visits. A
Bonferroni post hoc test was used to assess the significance of mean differences between these
groups (Dunn, 1961). The resulting statistics provided evidence relevant to a proportional
relationship between the number of CHC interactions and the magnitude of the changes in
marker results.
Data Interpretation
For all three Specific Aims, a stepwise regression model was created to provide evidence
relevant to each research question for each marker difference or health score difference. The
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results were presented as a series of numbered models, one for the addition of each predictor,
regardless of whether the predictor was considered a CV or the IV. The first model identified the
predictor that explained the greatest proportion of the variance in the DV. The next model
identified the predictor that explained the greatest proportion of the remaining variance in the
DV. This process was repeated until the addition of the next predictor resulted in a model that
was no longer statistically significant. This process generated from one to four models that
revealed the statistically significant CVs, and the IV. For each marker, a model summary table
was constructed with the R, R2, R2 change, F-score change, and the significance of the change in
F-score. The R2 represents the proportion of the variance in the DV that is explained by the CV
or IV. The change in R2 represents the change in variance explained with the addition of each
CV, if applicable. The change in F-statistic and accompanying p value indicate the significance
of each CV when added to the model, as well as the significance of the addition of the IV in the
final model.
For Aims 1and 2, an initial t-test determined if there was a statistically significant
difference in the unadjusted means between the CHC and non-CHC groups. The ANCOVA
generated for Specific Aims 1 and 2 determine if there were statistically significant differences in
the mean changes in the DV between those who had CHC interactions and those who did not.
The significance of the final model would also determine if the addition of the IV to the model
explained a statistically significant amount of that difference.
For Specific Aim 3, the F-score change and accompanying p values only indicate the
effect of the addition of each CV on the change in BMI or marker value and the number of CHC
interactions. Since the number of CHC interactions is not a categorical level of measurement, an
ANCOVA was not utilized to provide a statement of significance concerning the difference
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between the IV groups. However, ANCOVA was used to describe statistically significant
relationships between marker difference and number of CHC visits. Subjects were grouped
based on the number of CHC interactions they had. There was a group with one visit, another
with two visits, one with three visits, and if needed, a group for four or more visits. Groups were
created for each marker to ensure that each group was as equal in size as possible to preserve
homogeneity of variance between the groups. Differences in mean BMI and marker differences
between groups was determined by a one-way ANOVA and pairwise comparisons. In these
situations, a summary table for the ANOVA and a table of paired comparisons, with a
Bonferroni adjustment was presented.
Chapter Summary
Chapter 3 discussed information on the study methodology. Information was provided
concerning the population and sampling strategies employed, as well as details concerning how
the data was acquired from two data courses and merged. Steps required for data cleaning were
discussed, along with how the data was analyzed for each Specific Aim. Finally, Chapter 3
concluded with an explanation of how the data was examined and interpreted for statistical
significant findings.
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Chapter 4: Results

Introduction
Chapter 4 describes the subject demographics generated for all dependent variables
across all three Aims. In addition, sample selection for each biomarker is presented, along with
sample exclusion criteria and resulting sample sizes. Next, Chapter 4 provides statistical
evidence related to all three aims; diabetes related disease markers related to CHC interaction,
diabetes related disease markers related to health scores, and diabetes related disease markers
related to CHC frequency.
Specific Aim 1
The purpose of Aim 1 was to determine if there are statistically significant differences
between subjects who do or do not participate in CHC interactions in their changes in blood
glucose concentration, %HbA1c, blood 1,5-AG, blood insulin concentration, blood C-peptide
concentration, blood proinsulin concentration, and BMI. Before statistical analysis was
performed, the data set was cleaned and reviewed for univariate and multivariate outliers. The
results of this process are presented for each marker, following the summary tables for the
changes before and after adjustment for covariates.
The changes in markers were determined by subtracting the subjects’ follow-up marker
values from their initial marker values. A negative change indicates an improvement in glucose
homeostasis, with the exception of 1,5-AG. For 1,5-AG, a positive change in marker value
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indicates an improvement. Table 14 displays the mean changes in markers before adjustment for
covariates. The group of subjects who interacted with CHCs showed significantly greater
improvements in insulin, proinsulin, and BMI than the group with no CHC interactions. Both
groups showed worsening of %HgbA1c and 1,5-AG. However, the differences between the
groups was not statistically significant.
Table 14: Mean Changes in Markers of Glucose Homeostasis in Subjects with and without CHC
Interactions, and their Statistical Significance
Test
Glucose
(mg/dL)
HbA1c
(%)
Insulin
(μU/mL)
C-Peptide
(ng/mL)
Proinsulin
(pmol/L)
1,5-AG
(µg/mL)
BMI

CHCa

NonCHCb

-0.57

0.08

0.10

0.11

-0.78

-0.11

-0.11

-0.03

-1.17

0.23

-0.37

-1.29

-0.49

-0.20

a.)subjects who interacted with CHCs.

F
1.195
0.790
7.369
1.838
4.163
1.300
33.878

df
1
1
1
1
1
1
1

p value
0.275
0.374
0.007
0.176
0.042
0.256
<0.001

b.)subjects who did not interact with CHCs

To investigate the role of potential covariates on the mean change in the marker results,
linear regression was used to evaluate the change in model significance with stepwise additions
of the CVs age, sex, initial BMI, and initial marker value, and the IV, the use of CHCs. The
results of this analysis, summarized in Table 15, revealed that the initial result for each marker
was a significant covariate with CHC-patient interactions for the change in that marker. Other
covariates influenced some, but not all markers. After adjusting for the covariates, only the
change in BMI was significantly different between subjects with CHC interactions and those
without CHC interactions.
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Table 15: The Significance of CHC Interactions After Adjusting for Covariates on the Difference
Between the Change in Biomarkers

Test
Glucose
(mg/dL)
HbA1c
(%)
1,5-AG
(µg/mL)
Insulin
(μU/mL)
C-Peptide
(ng/mL)
Proinsulin
(pmol/L)
BMI

Mean
Marker
Change
CHC

Mean
Marker
Change
Non-CHC

Significant
Covariates

-0.57

0.08

Initial glucose, Age,
sex

0.546

0.10

0.11

Initial HbA1c

0.768

-0.37

-1.29

Initial 1,5-AG

0.379

-0.78

-0.11

-0.11

-0.03

-1.17

0.23

-0.49

-0.20

Initial insulin, BMI,
sex
Initial C-peptide,
BMI, Age
Initial proinsulin,
sex, age, BMI
Initial BMI

Significance of
CHC
Interactions
(p value)

0.112
0.453
0.104
< 0.001

Subject selection and results of analysis of the change in blood glucose
concentration. The initial number of available subjects was 171,614. Subjects that did
not fast for at least 8 hours were excluded from the analysis of the change in glucose
concentration. Subjects that did not have both an initial and a follow-up measurement of glucose
concentration were also excluded. After these exclusions, 16,150 subjects remained with 992
having CHC interactions and 15,158 without CHC interactions. From this sample of subjects,
one was removed for having a BMI < 15, and 100 were removed for having a BMI > 52.26. Z
scores were generated to identify univariate outliers, yielding 124 subjects with changes in
glucose concentration corresponding to z scores <-3.3, and 122 with a z score > 3.3. These
subjects were eliminated prior to random selection of subjects without CHC interaction. Prior to
randomization, 15,803 subjects remained with 969 having had CHC interactions and 14,834
without CHC interactions. After randomization, 1944 total subjects remained. To eliminate
multivariate outliers, a Mahalanobis Distance (MD) was generated using study number as the
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DV, and age, sex, initial BMI, CHC yes or no, initial insulin, and difference in BMI as the IVs.
The cutoff for Chi Square table with 6 degrees of freedom is 22.46, indicating that a MD > 22.46
would be considered an outlier (Pearson and Hartly, 1958). Based upon the MD generated, 49
subjects showed multicollinearity with MD > 22.46. These were removed from the dataset for
prior to the statistical . Table 16 describes the subject demographics for the glucose biomarker
sample.
Table 16: Demographics and Change in Glucose Concentrations for Subjects With and Without
CHC Interactions
CHC
Interactions
Yes
n= 962
No
n=964
Total
n =1926

Initial BMI

Initial
Glucose
(mg/dL)

Change in
Glucose
(mg/dL)

33% M
67% F

30.0
6.6

99.2
22.8

-0.57
12.77

54.5
14.2

45% M
55% F

28.8
6.0

98.1
24.2

0.08
13.31

55.2
13.8

39% M
61% F

29.4
6.3

98.8
23.5

-0.24
13.04

Initial
Age

Sex

Mean
SD

56.0
13.4

Mean
SD
Mean
SD

Statistical analysis using a t-test in SPSS revealed there was no statistically significant
difference in the mean change in glucose concentration between subjects that utilized CHC
interactions and those who do not with 95% confidence (p = 0.275).
Covariates were entered stepwise into a linear regression model, with each subsequent
model including the previous CVs and the newly entered CV. The model summary table is
shown in Table17. The final model includes initial glucose concentration, age, and sex as
significant CVs and the IV. Initial glucose concentration accounted for 11.1 % of the variance in
the model, while, age and sex accounted for 0.8 and 0.5 % respectively. After adjusting for initial
glucose, age and sex, linear regression confirmed no statistically significant difference in the
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mean change in glucose concentration between those who did (- 0.57 mg/dL), and those who did
not (0.08 mg/dL), participate in CHC interactions, (p=0.546).
Table 17: Significance of Covariates and CHC Interactions on the Mean Change in Glucose
Concentration
Model

Model
Components

R

R2

R2 Change

F Change

p value

1

Initial Glucose

.334

.111

.111

241.063

< 0.001

.346

.119

.008

17.797

< 0.001

.353

.125

.005

11.660

0.001

.354

.125

.000

.365

0.546

2
3

4

Initial Glucose,
Age
Initial Glucose,
Age, Sex
Initial Glucose
Age
Sex
CHC Y/N

Subject selection and results of analysis of the change in %HbA1c. The initial
number of available subjects was 38,320. Fifty-four subjects had results below the AMR for
either their initial or follow-up result, and were excluded. After excluding subjects that did not
have both initial and follow-up results, 38,266 subjects remained, with 1,368 having had CHC
interactions and 36,898 without CHC interactions. There were 290 subjects with BMI > 52.26
and 1 case with BMI < 15. These subjects were also excluded. Next, extreme cases of changes
in marker results were identified, using the extreme values in the SPSS explore function. Values
that fell outside 3 times the interquartile range (IQR) were deemed extreme values (Tukey,
1977). One subject was excluded due to a change in %HgbA1c > -9, and 13 subjects were
excluded due to a change in %HgbA1c > 7.
Prior to randomization, 37, 954 subjects remained, 1,357 with CHC interactions, and
36,597 without CHC interactions. To eliminate multicollinearity outliers, a MD was generated
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using study number as the DV and age, sex, initial BMI, CHC yes or no, initial %HbA1c, and
difference in BMI as the IVs. The cutoff for chi square table with 6 degrees of freedom is 22.46,
indicating that a MD > 22.46 would be considered an outlier (Pearson and Hartly, 1958). Based
upon the MD generated, 85 cases were deemed multivariate outliers and were excluded prior to
the statistical analysis. Table 18 describes the subject demographics for the HbA1c biomarker
sample.
Table 18: Demographics and Change in %HbA1c for Subjects With and Without CHC
Interactions
CHC
Interactions
Yes
n= 1315
No
n=1295
Total
n =2610

Initial BMI

Initial
HbA1c
(%)

Change in
HbA1c (%)

45% M
55% F

30.4
6.8

5.60
0.67

0.10
0.40

55.9
14.0

46% M
54% F

29.5
6.4

5.56
0.69

0.11
0.39

50.6
15.1

46% M
54% F

29.9
6.6

5.58
5.68

0.10
0.40

Initial
Age

Sex

Mean
SD

45.3
14.4

Mean
SD
Mean
SD

Statistical analysis using a t-test in SPSS revealed no statistically significant difference in
the mean change in %HbA1c between those that utilized CHCs and those who did not (p =
0.374). The mean change in %HbA1c was positive for both the CHC (0.10%) and non-CHC
(0.11%) groups, indicating an increase in average blood glucose concentration over time.
Covariates were entered stepwise into a linear regression model, with each subsequent
model including the previous CVs and the newly entered CV. The model summary table is
shown as Table 19. The only significant CV was the initial %HbA1c, which accounted for 15.4%
of the variance. After adjusting for initial %HbA1c, linear regression confirmed
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no statistically significant difference in the change in %HbA1c between those who did, and those
who did not have CHC interactions (p=.768).
Table 19: Significance of Covariates and CHC Interactions on the Mean Change in %HbA1c
Model
1
2

Model
Components
Initial
%HbA1c
Initial
%HbA1c
CHC Y/N

R

R2

R2 Change

F Change

p value

.392

.154

.154

473.571

< 0.001

.392

.154

.000

0.87

0.768

Subject selection and results of analysis of the change in 1,5-AG concentration. The
initial number of available subjects for 1,5-AG was 150. Five subjects had results below the
AMR and were excluded. Only 145 subjects remained with 25 having CHC interactions and 120
without CHC interactions. One subject had a BMI > 55.26 and was excluded. Z scores were used
to identify outliers for the change in 1,5-AG. Two subjects had z scores greater than 3.3,
corresponding to a change in 1,5-AG greater than 18 µg/mL. Randomization of the subjects
without CHC interactions was not performed since the number of subjects with CHC interactions
was > 10% of the number of subjects without CHC interactions. No multivariate outliers were
identified. Table 20 describes the subject demographics for the 1,5-AG biomarker sample.
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Table 20: Demographics and Change in 1,55-AG Concentrations for Subjects With and Without
CHC Interactions
Start age

Sex

Initial BMI

Initial
1,5-AG
(µg/mL)

Change in
1,5-AG
(µg/mL)

Mean
SD

51.5
15.0

36% M
64% F

28.4
5.6

15.80
9.01

-0.37
3.67

Mean
SD

50.3
15.23

33% M
67% F

28.2
6.9

17.05
6.81

-1.29
3.64

Mean
SD

50.6
15.15

34% M
66% F

28.3
6.7

16.83
7.23

-1.13
3.7

CHC
Interactions
Yes
n= 25
No
n=117
Total
n =142

Statistical analysis using a t-test in SPSS revealed no statistically significant difference in
the mean change in 1,5-AG between those with CHC interactions and those without CHC
interactions ( p=0.256).
Covariates were entered stepwise into a linear regression model, with each subsequent
model including the previous CVs and the newly entered CV. The model summary table is
shown as Table 21. The only significant CV was the initial 1,5-AG, which accounted for 19.2%
of the variance. After adjusting for initial 1,5-AG, linear regression confirmed
no statistically significant difference mean change in 1,5-AG between those who did, and those
who did not have CHC interactions (p=0.379).
Table 21: Significance of Covariates and CHC Interactions on the Mean Change in 1,5-AG
Concentration
Model
1
2

Model
Components
Initial 1,5-AG
Initial 1,5-AG
CHC Y/N

R

R2

R2 Change

F Change

p value

.438

.192

.192

33.171

< 0.001

.443

.196

.005

.779

0.379
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Subject selection and results of analysis of the change in insulin concentration. The
initial number of available subjects for insulin was 123,401. Subjects that did not fast for at least
8 hours were excluded from the analysis of the change in insulin concentration. Subjects that did
not have both an initial and a follow-up measurement of insulin concentration were also
excluded. After exclusions, 15,629 subjects remained with, 1,031 having CHC interactions and
14,344 without CHC interactions. From this sample, one was eliminated for having a BMI < 15
and 105 for having a BMI < 52.26. Z scores were generated to identify univariate outliers,
yielding 69 subjects with changes in insulin corresponding to z score >3.3 and 79 with a z score
<-3.3. These subjects were eliminated prior to random selection of subjects without CHC
interactions. Prior to randomization, 15,375 subjects remained, with 1031 having had CHC
interactions, and 14,344 without CHC interactions. After randomization, 2023 subjects remained.
To evaluate multivariate outliers, a MD was generated using study number as the DV and age,
sex, initial BMI, CHC yes or no, initial insulin, and difference in BMI as the IVs. The cutoff for
chi square table with 6 degrees of freedom is 22.46, indicating that a MD > 22.46 would be
considered an outlier (Pearson and Hartly, 1958). Based upon the MD generated, 40 subjects
showed to have multivariate outliers with MD > 22.46. These were removed and analysis ran.
Table 22 describes the patient demographics for the insulin biomarker sample.
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Table 22: Demographics and Change in Insulin Concentrations for Subjects With and Without
CHC Interactions
Initial
Age

Sex

Initial BMI

Initial
Insulin
(μU/mL)

Change in
Insulin
(μU/mL)

Mean
SD

55.6
13.8

34% M
66% F

30.0
6.4

11.9
7.5

-0.78
5.65

Mean
SD

54.1
13.2

40% M
60% F

28.7
6.2

10.7
7.2

-0.11
5.31

Mean
SD

54.9
13.5

37% M
63% F

29.4
6.4

11.3
7.4

-0.45
5.50

CHC
Interactions
Yes
n= 973
No
n=1010
Total
n =1983

Statistical analysis using a t-test in SPSS revealed a statistically significant difference in
the mean change in inulin between those with CHC interactions and those without CHC
interactions (p=0.007).
Covariates were entered stepwise into a linear regression model, with each subsequent
model including the previous CVs and the newly entered CV. The model summary table is
shown as Table 23.
Table 23: Significance of Covariates and CHC Interactions on the Mean Change in Insulin
Concentration
Model
1
2
3

4

Model
Components
Initial Insulin
Initial Insulin
Initial BMI
Initial Insulin,
Initial BMI
Sex
Initial Insulin
Initial BMI
Sex
CHC Y/N

R

R2

R2 Change

F Change

p value

.401

.161

.161

380.081

< 0.001

.426

.181

.020

48.825

< 0.001

.431

.186

.005

11.369

0.001

.432

.187

.001

2.523

0.112
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The final model included initial insulin, initial BMI, and sex as CV and the IV, use of
CHC. Initial insulin accounted for 16.1% of the variance in the model, while initial BMI and sex
accounted for 2% and 0.5% respectively. After adjusting for initial insulin, initial BMI and sex,
linear regression confirmed no statistically significant difference was detected for the change in
mean insulin between those who did ( -0.78 μU/mL), and those who did not (-0.11 μU/mL),
participate in CHC interactions ( p = 0.112).
Subject selection and results of analysis of the change in C-peptide concentration.
The initial number of available subjects for C-peptide was 28,415. Subjects that did not fast for
at least 8 hours were excluded from the analysis of chance in C-peptide concentration Subjects
that did not have both an initial and a follow-up measurement of C-peptide concentration, and/or
that had results outside the AMR, were also excluded. After these exclusions, 3,816 subjects
remained with 414 having had CHC interactions and 3,402 that did not. From this sample of
subjects, one was eliminated for having a BMI < 15 and 76 were eliminated for having a BMI >
52.26. Z scores were generated to identify univariate outliers, yielding 24 subjects with changes
in C-peptide concentration corresponding to z score >3.3 and 26 with a z score <-3.3. Prior to
random selection of the non-CHC groups, 3,739 subjects remained. After randomization, 832
subjects remained. The MD was generated using study number as the DV and age, sex, initial
BMI, CHC yes or no, initial insulin, and difference in BMI as the IVs. The cutoff for chi square
table with 6 degrees of freedom is 22.46, indicating that a MD > 22.46 would be considered an
outlier (Pearson and Hartly, 1958). Based upon the MD generated, nine subjects were considered
multivariate outliers with MD > 22.46. These were removed and analysis ran. Table 24
describes the patient demographics for the insulin biomarker sample.
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Table 24: Demographics and Change in C-peptide Concentrations for Subjects With and Without
CHC Interactions
Initial
Age

Sex

Initial BMI

Initial
C-peptide
(ng/mL)

Change in
C-peptide
(ng/mL)

Mean
SD

56.1
14.0

32% M
68% F

30.2
6.2

3.02
1.34

-0.10
0.83

Mean
SD

52.5
14.6

41% M
59% F

29.2
6.5

2.76
1.26

-0.03
0.73

Mean
SD

54.24
14.413

37% M
63% F

29.7
6.3

2.88
1.30

-0.07
0.78

CHC
Interactions
Yes
n= 401
No
n=422
Total
n =832

Statistical analysis a t-test in using SPSS revealed no statistically significant difference in
the mean change in C-peptide concentrations between subjects that utilized CHCs and those who
did not (p = 0.176).
Covariates were entered stepwise into a linear regression model, with each subsequent
model including the previous CVs and the newly entered CV. The model summary table is
shown as Table 25.
Table 25: Significance of Covariates and CHC Interactions on the Mean Change in C-peptide
Concentration
Model
1
2
3

4

Model
Components
Initial C-peptide
Initial C-peptide
Initial BMI
Initial C-peptide
Initial BMI
Start Age
Initial C-peptide
Initial BMI
Start Age
CHC Y/N

R

R2

R2 Change

F Change

p value

.351

.123

.123

115.356

< 0.001

.374

.140

.016

15.605

< 0.001

.380

.145

.005

4.839

0.028

.381

.145

.001

.563

0.453
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The final model includes initial C-peptide concentration, initial BMI, and age as
significant CVs, and the DV change in C-peptide. Initial C-peptide accounted for 12.3% of the
variance in the model, while initial BMI and age accounted for 1.6% and 0.5% variance
respectively. After adjusting for initial C-peptide, initial BMI, and age, linear regression
confirmed no statistically significant difference was detected for the change in mean C-peptide
between those who did (- 0.11 ng/mL), and those who did not (0.03 ng/mL), participate in CHC
interactions (p = 0.453).
Subject selection and results of analysis of the change in proinsulin concentration.
The initial number of available subjects for proinsulin was 18,788. Subjects that did not fast for
at least 8 hours were excluded from the analysis of change in proinsulin concentration. Subjects
that did not have both an initial and follow-up measurement of proinsulin were also excluded.
Additionally, 51 subjects had results below the AMR and were excluded. After these exclusions,
2,356 subjects remained with 282 having CHC interactions and 2,074without CHC interactions.
From this sample of subjects, 17 subjects were eliminated for BMI < 52.26. Z scores were
generated to identify outliers yielding 18 subjects with change in proinsulin concentration
corresponding to a z scores >3.3, and 18 with z scores < -3.3. These subjects were eliminated
prior to random selection of subjects without CHC interactions. After randomizations, 523
subjects remained. To eliminate multivariate outliers, a MD was generated using study number
as the DV and age, sex, initial BMI, the number of CHC Interactions, initial proinsulin, and
difference in BMI as the IVs. The cutoff for chi square table with 6 degrees of freedom is 22.46,
indicating that a MD > 22.46 would be considered an outlier (Pearson and Hartly, 1958). Based
upon the MD generated, 11 subjects were considered multivariate outliers with MD > 22.46.
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These 11 subjects were removed and analysis ran. Table 26 describes the patient demographics
for the proinsulin biomarker sample.
Table 26: Demographics and Change in Proinsulin Concentrations for Subjects With and
Without CHC Interactions
Initial
Age

Sex

Initial BMI

Initial
Proinsulin
(pmol/L)

Change in
Proinsulin
(pmol/L)

Mean
SD

55.5
14.4

33% M
67% F

30.1
6.2

14.72
10.47

-1.17
7.92

Mean
SD

53.0
14.8

44% M
56% F

28.9
6.2

13.28
9.42

0.23
7.71

Mean
SD

54.3
14.6

38%M
62% F

29.5
6.2

14.03
10.00

-0.50
7.84

CHC
Interactions
Yes
n= 274
No
n=249
Total
n =523

Statistical analysis using a t-test in SPSS revealed a statistically significant difference in
the mean change in proinsulin concentration between those that utilized CHC interactions and
those who did not (p = 0.042).
Covariates were entered stepwise into a linear regression model, with each subsequent
model including the previous CVs and the newly entered CV. The model summary table is
shown in Table 27. The final model includes, initial proinsulin, sex, age, and initial BMI as
significant CVs, and the DV change in proinsulin. Initial proinsulin concentration accounted for
11.4% of the variance in the model, while sex, age and initial BMI accounted for 1.3, 0.9 and
0.7% respectively. After adjusting for initial proinsulin, sex, age, and initial BMI, linear
regression confirmed no statistically significant difference was detected for the change in
proinsulin concentration between those who did (-1.17 pmol/L), and those who did not (0.23
pmol/L), participate in CHC interactions (p = 0.104).
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Table 27: Significance of Covariates and CHC Interactions on the Mean Change in Proinsulin
Concentration
Model Model Components
1
2
3

4

5

Initial Proinsulin
Initial Proinsulin
Sex
Initial Proinsulin
Sex
Start Age
Initial Proinsulin
Sex
Start Age
Initial BMI
Initial Proinsulin
Sex
Start Age
Initial BMI
CHC Y/N

R

R2

R2 Change

F Change

p value

.338

.114

.114

67.084

< 0.001

.357

.127

.013

7.983

0.005

.370

.137

.009

5.605

0.018

.379

.143

.007

4.042

0.045

.385

.148

.004

2.654

0.104

Subject selection and results of analysis of the change in BMI. Subjects that did not
have both an initial and follow-up BMI were excluded. After exclusion, 88,747 subjects
remained for BMI analysis with 4,029 having CHC interactions and 84,718 without CHC
interactions. For BMI, randomization occurred before univariate outlier investigation, generating
8072 total subjects. From this sample, 77 subjects were removed for having a BMI > 52.26. Z
scores were generated to identify univariate outliers, yielding 74 subjects with a change in BMI
corresponding to a z score < -3.3, and 67 with a z score > 3.3. These subjects were removed,
leaving 7854 subjects for analysis.
To eliminate multivariate outliers, MD was generated using study number as the DV and
age, sex, initial BMI, CHC yes or no, and difference in BMI as the IVs. The cutoff for chi square
table with 5 degrees of freedom is 20.52, indicating that a MD > 20.52 would be considered an
outlier (Pearson and Hartly, 1958). Based on the MD generated, 49 subjects were considered
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multivariate outliers with MD > 20.52. These 49 subjects were removed and analysis ran. Table
28 describes the patient demographics for the proinsulin biomarker sample.
Table 28: Demographics and Change in BMI for Subjects With and Without CHC Interactions
CHC
Interactions
Yes
n= 3893
No
n=3912
Total
n = 7805

Initial
Age

Sex

Initial BMI

Change in
BMI

Mean
SD

57.9
13.5

52% M
48% F

30.0
6.5

-0.49
2.22

Mean
SD

56.7
14.0

44% M
56% F

29.2
6.2

-0.20
2.16

Mean
SD

57.3
13.8

48% M
52% F

29.6
6.4

-0.34
2.21

Statistical analysis using a t-test in SPSS revealed a statistically significant difference in
the mean change in BMI between those that utilized CHC interactions and those who did not (p
< 0.001).
Covariates were entered stepwise into a linear regression model, with each subsequent
model including the previous VCs and the newly entered CV. The model summary table is
shown as Table 29.
Table 29: Significance of Covariates and CHC Interactions on the Mean Change in BMI
Model
1
2

Model
Components
Initial BMI
Initial BMI
CHC Y/N

R

R2

.235a

.055

R2
Change
.055

.241b

.058

.003

F Change

p value

456.735

< 0.001

21.938

< 0.001

The final model only included initial BMI as a significant CV, and the DV change in
BMI. Initial BMI accounted for 5.5% of the variance explained. After adjusting for initial BMI,
linear regression confirmed a statistically significant difference was detected for the change in
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mean BMI between those who did (-0.49), and those who did not (- 0.20, participate in CHC
interactions (p = < 0.001).
Specific Aim 2
The purpose of Specific Aim 2 was to determine if statistically significant differences
exist in the change in glucose, %HgbA1c, and BMI health scores between subjects who did and
those who did not interact with CHCs. Before statistical analysis was performed, the data set was
reviewed for univariate and multivariate outliers. The follow section presents the results of data
cleaning and subject exclusion for each marker and BMI.
For Specific Aim 2, regression was performed using the change in health score as the
DV. The IV was the use or withholding of CHC interaction or no interaction, with BMI, sex, and
age at the subjects’ initial visit as potential CVs. The change in health score was determined by
subtracting the subjects’ marker health score at their follow-up blood draw from their marker
health score at their initial blood draw. A negative change corresponds to an improvement in the
health score for that particular marker, while a positive change corresponds to a worsening of the
health score for that marker. The mean change in health score for %HbA1c, glucose, and BMI
was calculated for both the CHC and non-CHC groups. Table 30 describes marker means for
each group and the unadjusted t-test results of the comparison of change in health scores.
Table 30: Mean Changes in Glucose, %HbA1c, and BMI Health Scores in Subjects with and
without CHC Interactions, and their Statistical Significance
Test
Glucose
HbA1c
BMI

CHCa

NonCHCa

-0.2

0.02

0.09

0.10

-0.07

a.)subjects who interacted with CHCs.

F
3.562
0.081

-0.04

12.911

df

p value

1

0.059

1

0.776

1

<0.001

b.)subjects who did not interact with CHCs
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Table 31 describes the ANCOVA linear regression which revealed the significant CVs
for each marker, as well as the significance of the CHC and non-CHC groups differences.
Table 31: The Significance of CHC Interactions After Adjusting for Covariates on the Difference
Between the Change in Glucose, HbA1c, and BMI

Test

Mean Health
Score Change
CHC

Mean
Health Score
Change
Non-CHC

Glucose

-0.2

0.02

HbA1c
BMI

0.09
-0.07

0.10
-0.04

Significant CVs

Significance of
CHC
Interactions
(p value)

Initial glucose,
age, sex
Initial HbA1c
Initial BMI

0.165
0.949
< 0.001

Subject selection and results of analysis of the change in glucose health score. For
Specific Aim 2, the same 1944 subjects selected for the analysis of the changes in glucose
concentration were examined for the changes in glucose health score. Twenty-five of these
subjects exhibited a MD > 22.46, and were excluded from the analysis. The demographics of the
subjects utilized for the analysis are presented in Table 32.
Table 32: Demographics and Change in Glucose Health Score for Subjects With and Without
CHC Interactions
Initial
Age

Sex

Initial
BMI

Initial
Glucose
(mg/dL)

Initial
Health
Score

Change
in Health
Score

Mean
SD

56.1
13.4

33% M
67% F

30.1
6.6

97.9
17.5

0.40
0.62

-0.02
0.54

Mean
SD

54.6
14.2

45% M
55% F

28.7
5.9

96.8
18.0

0.36
0.60

0.02
0.52

Mean
SD

55.3
13.8

39% M
61% F

29.4
6.3

97.4
17.8

0.38
0.61

0.00
0.53

CHC
Interactions
Yes
n= 958
No
n= 961
Total
n = 1919

Statistical analysis using a t-test in SPSS revealed no statistically significant difference in
the mean change in glucose health score for those that utilized CHC interactions and those who
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did not (p = 0.059). Covariates were entered stepwise into a linear regression model, with each
subsequent model including the previous CVs and the newly entered CV. This analysis revealed
that initial glucose, age, and sex were significant CVs. Initial glucose accounted for 7.4% of the
variance, while age and sex explained 0.6% and 0.4% of the variance respectively. Engaging or
not engaging in CHC interactions only accounted for 0.1% of the variance. After adjusting for
initial glucose, age, and sex, linear regression confirmed that there was no statistically significant
difference in the change in mean glucose health score between those who did (-0.2), and those
who did not (0.02) participate in CHC interactions (p = 0.165). The model summary is shown in
Table 33. The final model includes all significant CVs and the DV.
Table 33: Significance of Covariates and CHC Interactions on the Mean Change in Glucose
Health Score
Model
1
2
3

4

Model
Components
Initial Glucose
Initial Glucose
Start Age
Initial Glucose
Start Age
Sex
Initial Glucose
Start Age
Sex
CHC Y/N

R

R2

.271

.074

.074

152.373

< 0.001

.283

.080

.006

13.426

< 0.001

.290

.084

.004

8.229

0.004

.291

.085

.001

1.927

0.165

R2 Change F Change

p value

Based upon their assigned health score for glucose concentration, subjects were classified
as normal, prediabetic, or diabetic. The distribution of these classifications between those who
did or did not have CHC interactions in shown in Table 34. For the group with CHC interactions,
the follow-up glucose health score showed a decrease in the number of subjects classified as
diabetic by 17, an increase in the number classified as prediabetic by 11, and an increase in the
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number classified as normal by six. For the group without CHC interactions, there was no
change in the number of subjects classified as diabetic, and an increase of 21 classified as
prediabetic.
Table 34: Classification of Subjects by Glucose Health Score
Initial Classification
CHC
Interactions
No CHC
Interactions
Total

Follow-up Classification

Normal

Prediabetic

Diabetic

Normal

Prediabetic

Diabetic

644

246

68

650

257

51

682

216

63

661

237

63

462

131

1311

494

114

1326

Subject selection and results of analysis of the change in HbA1c health score. For
Specific Aim 2, the same 2685 subjects selected for the analysis of the changes in %HgbA1c
were examined for the changes in %HgbA1c health score. There were 45 subjects with a MD >
22.46. These subjects were excluded from the analysis. The demographics of the subjects utilized
for the analysis are presented in Table 35.
Table 35: Demographics and Change in HbA1c Health Score for Subjects With and Without
CHC Interactions
Initial
Age

Sex

Initial
BMI

Initial
HbA1c

Initial
Health
Score

Change
in Health
Score

Mean
SD

45.3
14.4

45% M
55% F

30.4
6.8

5.6
0.75

0.43
0.66

0.09
0.48

Mean
SD

55.9
14.0

46% M
54% F

29.5
6.3

5.6
0.75

0.42
0.66

0.10
0.47

Mean
SD

50.58
15.1

45% M
55% F

30.0
6.6

5.6
0.75

0.43
0.66

0.10
0.47

CHC
Interactions
Yes
n= 1330
No
n= 1310
Total
n = 2640
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Statistical analysis using a t-test in SPSS revealed no statistically significant difference in
the mean change in %HbA1c health score for those that utilized CHC interactions and those who
did not (p = 0.776). Covariates were entered stepwise into a linear regression model, with each
subsequent model including the previous VCs and the newly entered CV. Only initial %HbA1c
was a statistically significant CV in the best fit model, accounting for 1.8% of the variance. After
adjusting for initial %HbA1c, linear regression confirmed no statistically significant difference in
the change in mean %HbA1c health score between those who did (0.09), and those who did not
(0.10) participate in CHC interactions (p = 0.949). The model summary is shown in Table 36.
The final model includes all significant CVs and the DV.
Table 36: Significance of Covariates and CHC Interactions on the Mean Change in HbA1c
Health Score
Model
1
2

Model
Components
Initial HbA1c
Initial HbA1c
CHC Y/N

R

R2

R2 Change

F Change

p value

.134

.018

.018

48.568

< 0.001

.134

.018

.000

.004

0.949

Based upon their assigned health score for %HgbA1c, subjects were classified as normal,
prediabetic, or diabetic. The distribution of these classifications between those who did or did not
have CHC interactions in shown in Table 37.
Table 37: Classification of Subjects by %HgbA1c Health Score
Initial Classification
CHC
Interactions
No CHC
Interactions
Total

Follow-up Classification

Normal

Prediabetic

Diabetic

Normal

Prediabetic

Diabetic

885

316

129

761

439

130

884

303

123

778

385

147

1769

619

252

1539

824

277
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For the group with CHC interactions, the follow-up glucose health score showed a
decrease in the number of subjects classified as normal by 124, with an increase in the number
classified as prediabetic by 123. For the group without CHC interactions, there was a decrease in
the number of subjects classified as normal by 106, with increases of 82 classified as prediabetic
and 24 classified as diabetic.
Subject selection and results of analysis of the change in BMI health score. For
Specific Aim 2, the same 7854 subjects selected for the analysis of the changes in BMI were
examined for the changes in BMI health score. There were 61 subjects with a MD > 20.52. These
61 subjects were excluded prior to analysis. The demographics of the subjects utilized for the
analysis are presented in Table 38.
Table 38: Demographics and Change in BMI Health Score for Subjects With and Without CHC
Interactions
CHC
Interactions
Yes
n= 3900
No
n= 3893
Total
n = 7793

Initial
Age

Sex

Initial
BMI

Initial
Change in
Classification Classification

Mean
SD

57.9
13.5

52% M
48% F

30.0
6.6

1.26
0.79

-0.07
0.42

Mean
SD

56.7
14.1

44% M
456% F

29.2
6.3

1.17
0.79

-0.04
0.41

Mean
SD

57.3
13.8

48% M
52% F

29.6
6.4

1.21
0.80

-0.05
0.42

Statistical analysis using a t-test in SPSS revealed that there was a significant difference
in the mean change in BMI health scores between subjects who had CHC interactions and those
who did not (p < 0.001). Covariates were entered stepwise into a linear regression model, with
each subsequent model including the previous CVs and the newly entered CV. Initial BMI was
the only significant CV, accounting for 0.4% of the variance, while CHC interactions accounted
for 0.6%. After adjusting for initial BMI, a statistically significant difference in the change in
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mean BMI health scores remained, between those who did (-0.07), and those who did not (-0.04),
participate in CHC interactions (p =0.001). The model summary table is shown as Table 39. The
final model includes all significant CVs and the DV.
Table 39: Significance of Covariates and CHC Interactions on the Mean Change in BMI Health
Score
Model
1
2

Model
Components
Initial BMI
Initial BMI
CHC Y/N

R

R2

.066
.075

.004
.006

R2 Change F Change
.004
.001

33.800
10.562

p value
< 0.001
< 0.001

Based upon their assigned health score for BMI, subjects were classified as normal,
overweight, or obese. The distribution of these classifications between those who did or did not
have CHC interactions in shown in Table 40.
Table 40: Classification of Subjects by BMI Health Score
Initial Classification
CHC
Interactions
No CHC
Interactions
Total

Follow-up Classification

Normal

Overweight

Obese

Normal

Overweight

Obese

840

1222

1838

945

1286

1669

935

1345

1613

987

1383

1523

1775

2567

3451

1932

2669

3192

For the group with CHC interactions, the follow-up BMI health score showed a decrease
in the number of subjects classified as obese by 169, with an increase in the number classified as
normal by 105, and an increase in the number classified as overweight by 64. For the group
without CHC interactions, there was a decrease in the number of subjects classified as obese by
90, with increases of 52 classified as normal and 38 classified as diabetic.
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Specific Aim 3
The purpose of Aim 3 was to determine the relationship between the number of CHC
interactions and magnitude of the change in blood glucose concentration, %HbA1c, blood 1,5AG, blood insulin concentration, blood C-peptide concentration, blood proinsulin concentration,
and BMI. Subjects were grouped according to whether they had 1, 2, 3, or >4 CHC interactions.
Before statistical analysis was performed, the data set was reviewed for univariate and
multivariate outliers. The sections following Table 41 describe how subjects were eliminated,
and the results of data cleaning for each marker and BMI.
Linear regression was performed using the change in each marker as the DV, and the
number of CHC interactions as the IV. A negative change in mean marker values would indicate
an improvement in that particular marker, with the exception of 1,5-AG. As with Specific Aims
1 and 2, initial BMI, sex, and age at the subject’s initial visit were used as potential CVs. Linier
regression provided an ANCOVA table. However, since the number of CHC visits were an
interval level of measurement, statements of significance of biomarker difference between those
who and did not utilize CHCs could not be provided. Linear regression could only determine the
significance of the number of CHC interactions on the change in the DV. In addition to linear
regression, the number of interactions were considered as a categorical variable and the
significance of the differences in the changes in marker results between the number of CHC
interactions was tested using ANOVA followed by a paired one way t-test. Results are reported
as Bonferroni post hoc mean comparisons to investigate the mean differences between the CHC
interaction groups. Table 41 provides a summary of results and between-group differences.
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Table 41: The Significance of the Number of CHC Interactions on the Change in Markers of
Glucose Homeostasis

Marker

Glucose
(mg/dL)
HbA1c
(%)
1,5-AG
(µg/mL)
Insulin
(μU/mL)

C-Peptide
(ng/mL)
Proinsulin
(pmol/L)
BMI

Best Model Including
Significant CVs

Significance of the
Number of CHC
Interactions
(p value)

Initial Glucose
Start Age
Sex
Initial BMI
# of CHC Interactions
Initial %HbA1c
# of CHC Interactions
Initial 1,5-AG
# of CHC Interactions
Initial Insulin
Initial BMI
Sex
# of CHC Interactions
Initial C-peptide
Initial BMI
Start Age
# of CHC Interactions
Initial Proinsulin
# of CHC Interactions
Initial BMI
# of CHC Interactions

Significance of
Between Number of
CHC Interaction
Differences
(p value)

No
p = 0.971

No
p > 0.05

Yes
p = 0.029
No
p = 0.229

No
p > 0.05
No
p > 0.05

Yes
p = 0.010

No
p > 0.05

No
p = 0.435

Yes
Between Groups 1-2
P = 0.035

No
p = 0.976
Yes
p < 0.001

No
p > 0.05
Between Groups 1-4
p < 0.001

Subject selection and results of analysis of the change in glucose concentration by
number of CHC interactions. There were 969 subjects that had at least one CHC
interaction. Mahalanobis distances were generated, replacing only CHC Y/N with the number of
interactions. Thirty-one subjects were identified with a MD > 22.46. These subjects were
excluded prior to the statistical analyses. To ensure that all CHC interaction groups had at least
10% of the number of subjects in the largest group, subjects with four or more interactions were
combined into one group. Table 42 details CHC interaction group demographics and change in
glucose concentration.
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Table 42: Demographics and Change in Glucose Concentration for Subjects by Number of CHC
Interactions
Initial
Age

Sex

Initial BMI

Initial
Glucose
(mg/dL)

Change in
Glucose
(mg/dL)

Mean
SD

54.6
13.4

34% M
66% F

29.4
6.4

96.9
16.0

-0.51
11.70

Mean
SD

56.8
13.0

34% M
66% F

30.0
6.4

98.4
18.0

-1.45
13.30

Mean
SD

57.4
13.2

26% M
74% F

31.0
6.8

95.9
14.3

0.41
12.46

Mean
SD

59.4
13.6

30% M
70% F

32.0
7.2

99.0
18.4

-0.44
13.10

Mean
SD

55.9
13.4

33%M
67% F

30.0
6.6

97.4
16.6

-0.64
12.30

CHC
Interactions
1
n= 522
2
n= 219
3
n= 90
4 or more
n= 107
Total
n = 938

Linear regression revealed no significant relationship between the mean change in
glucose concentration and the number of CHC interactions. Covariates were entered stepwise
into the linear regression model, with each subsequent model including the previous CVs and the
newly entered CV. The model summary is shown in Table 43. The final model includes all
significant CVs and the DV. For the change in glucose, the initial glucose accounted for 24.8%
of the variance. Age, sex and initial BMI explained 1.6%, 0.8 and 0.3% of the variance
respectively. The number of CHC interactions did not statistically account for any of the
variance. After adjusting for initial glucose, age, sex, and initial BMI, there was
no statistically significant relationship between the mean change in glucose and the number of
CHC interactions (p = 0.971).
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Table 43: The Effects of Covariates and the Number of CHC interactions on the Significance of
Mean Change in Glucose

.248

R2
Change
.248

F
Change
308.817

.514

.264

.016

20.222

< 0.001

.522

.272

.008

10.627

0.001

.525

.276

.003

4.471

0.035

.525

.276

.000

.001

0.971

Model

Model Components

R

R2

1

Initial Glucose
Initial Glucose
Start Age
Initial Glucose
Start Age
Sex
Initial Glucose
Start Age
Sex
Initial BMI
Initial Glucose
Start Age
Sex
Initial BMI
# of CHC Interactions

.498

2
3

4

5

p value
< 0.001

Graphical representation (Figure 3) suggests a decrease in mean change in glucose
between CHC interaction groups one and two, but an increase with CHC interaction group three.
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Figure 3: Mean Change in Glucose by Number of CHC Interactions
Error bars represent 95% Confidence Intervals

A Bonferroni multiple comparison table (Table 44) confirms that there was no
statistically significant difference in the mean change in glucose between CHC interactions
groups, (p < 0.05).
Table 44: Bonferroni Multiple Comparison for Glucose and Number of CHC Interactions
# of CHC
Interactions

Additional
Visit

Mean
Difference

Standard
Error

p value

1

2.00
3.00
4.00
1.00
3.00
4.00
1.00
2.00
4.00
1.00
2.00
3.00

.939
-.925
-.074
-.939
-1.863
-1.013
.925
1.863
.850
.074
1.013
-.850

0.991
1.406
1.307
0.991
1.542
1.452
1.406
1.542
1.761
1.307
1.452
1.761

1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000

2

3

4

93

95% CI of the
Difference
Upper Lower
3.56
2.79
3.38
1.68
2.21
2.83
4.64
5.94
5.51
3.53
4.85
3.81

-1.68
-4.64
-3.53
-3.56
-5.94
-4.85
-2.79
-2.21
-3.81
-3.38
-2.83
-5.51

Subject selection and results of analysis of the change in %HbA1c by number of
CHC interactions. There were only 1,357 subjects that had at least one CHC
interactions. Mahalanobis distance was generated replacing only CHC Y/N with the number of
CHC Interactions. Fifty-one subjects were identified with a MD > 22.46. These subjects were
excluded prior to the statistical analysis. To ensure all groups had at least 10% of the largest
group, subjects with more than four interactions were combined in to one group, four or more.
Table 45 details CHC interaction group demographics and change in %HbA1c.
Table 45: Demographics and Change in %HbA1c for Subjects by CHC Number of Interactions
Initial
Age

Sex

Initial BMI

Initial
HbA1c
(%)

Change in
HbA1c (%)

Mean
SD

45.2
14.3

42% M
58% F

29.4
6.6

5.54
0.65

0.12
0.37

Mean
SD

45.2
14.2

48% M
52% F

31.3
6.8

5.71
0.81

0.08
0.42

Mean
SD

45.7
14.5

44% M
56% F

31.0
6.7

5.69
0.68

0.03
0.43

Mean
SD

46.2
15.5

55% M
45% F

32.9
7.2

5.61
0.67

0.04
0.46

Mean
SD

45.3
14.4

45%M
55% F

30.4
6.8

5.61
0.70

0.09
0.40

CHC
Interactions
1
n= 736
2
n=298
3
n=124
4 or more
n=148
Total
n =1306

Linear regression revealed there was a significant relationship between the mean change
in %HbA1c and the number of CHC interactions.
Covariates were entered stepwise into the linear regression model, with each subsequent
model including the previous CVs and the newly entered CV. The model summary is shown in
Table 46. The final model includes all significant CVs and the DV. For Change in HbA1c, initial
HbA1c accounted for 20.1% of the variance explained. The addition of the number of CHC
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interactions into the model was also significant, explaining 0.3 % of variance. After adjusting for
initial %HbA1c, analysis confirmed a statistically significant relationship between the mean
change in %HbA1c and the number of CHC interactions (p = 0.029).
Table 46: The Effects of Covariates and the Number of CHC interactions on the Significance of
Mean Change in %HbA1c
Model

Model Components

R

R2

R2
Change

F Change

p value

1

Initial HbA1c

.448

.201

.201

327.027

< 0.001

2

Initial HbA1c
# of CHC Interactions

.451

.203

.003

4.752

0.029

Graphical representation (Figure 4) suggests a decrease in the mean change in HbC1a as
the number of CHC interactions increases until three CHC interactions.

Figure 4: Mean Change in HbA1c by Number of CHC Interactions
Error bars represent 95% Confidence Intervals
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A Bonferroni multiple comparison table (Table 47) confirms that there was no
statistically significant difference in the mean change in HbA1c between CHC interactions
groups, (p >0.05).
Table 47: Bonferroni Multiple Comparison for HbA1c and Number of CHC Interactions
# of CHC
Interactions

Additional
Visit

Mean
Difference

Standard
Error

p value

1

2.00
3.00
4.00
1.00
3.00
4.00
1.00
2.00
4.00
1.00
2.00
3.00

.039
.093
.079
-.039
.054
.040
-.093
-.054
-.014
-.079
-.040
.014

.028
.039
.036
.028
.043
.040
.039
.043
.049
.036
.040
.049

0.952
0.105
0.177
0.952
1.000
1.000
0.105
1.000
1.000
0.177
1.000
1.000

2

3

4

95% CI of the
Difference
Upper Lower
0.111
0.196
0.175
0.034
0.167
0.147
0.010
0.060
0.115
0.017
0.067
0.143

-0.034
-0.010
-0.017
-0.112
-0.059
-0.067
-0.196
-0.167
-0.143
-0.174
-0.147
-0.115

Subject selection and results of analysis of the change in 1,5-AG by number of CHC
interactions. There were 25 subjects that had at least one CHC interactions.
Mahalanobis distance was generated replacing only CHC Y/N with the number of CHC
Interactions. To ensure all groups had at least 10% of the largest group subjects with three or
more interactions were combined. Table 48 describes the demographics and change in 1,5-AG
concentration for each CHC interaction group.
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Table 48: Demographics and Change in 1,5-AG Concentration for Subjects by Number of CHC
Interactions
Initial
Age

Sex

Initial BMI

Initial 1,5AG
(µg/mL)

Change in
1,5-AG
(µg/mL)

Mean
SD

45.2
14.6

33% M
67% F

26.2
5.9

16.34
8.57

-0.98
2.10

Mean
SD

52.9
14.3

29% M
71% F

30.5
5.9

14.63
7.02

-0.80
1.01

Mean
SD

62.8
10.8

50% M
50% F

30.3
3.1

16.07
12.91

1.33
7.01

Mean
SD

51.6
15.0

36%M
64% F

28.4
5.6

15.80
9.02

-0.37
3.67

CHC
Interactions
1
n= 12
2
n=7
3
n=6
Total
n =25

Linear regression revealed no significant relationship between the mean change in 1,5AG concentration and the number of CHC interactions.
Covariates were entered stepwise into a linear regression model, with each subsequent
model including the previous CVs and the newly entered CV. The model summary table is
shown as Table 49. The final model includes all significant CVs and the DV. For change in 1,5AG, initial 1,5-AG accounted for 21.8% of the variance explained. The number of CHC
interactions did not statistically account for any variance explained. After adjusting for initial
1,5AG, there was no statistically significant relationship between the mean change in glucose
and the number of CHC interactions (p = 0.229).
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Table 49: The Effects of Covariates and the Number of CHC interactions on the Significance of
Mean Change in 1,5-AG
Model

Model Components

R

R2

R2
Change

F
Change

p value

1

Initial 1,5-AG

.467

.218

.218

6.427

0.018

2

Initial 1,5-AG
# of CHC Interactions

.519

.269

.051

1.530

0.229

Graphical representation (Figure 5) suggests a trending increase in the mean change of
1,5-AG between CHC interaction groups one and three.

Figure 5: Mean Change in 1,5-AG by Number of CHC Interactions
Error bars represent 95% Confidence Intervals

A Bonferroni multiple comparison table (Table 50) confirms no statistically significant
difference in the mean change in 1,5-AG between CHC interactions groups, (p >0.05).
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Table 50: Bonferroni Multiple Comparison for 1,5-AG and Number of CHC Interactions
# of CHC
Interaction

Additional
Visit

Mean
Difference

Standard
Error

p value

1

2.00
3.00
1.00
3.00
1.00
2.00

-.171
-2.305
0.171
-2.134
2.305
2.134

1.759
1.849
1.759
2.057
1.849
2.057

1.000
0.677
1.000
0.932
0.677
0.932

2
3

95% CI of the
Difference
Upper
Lower
4.386
-4.728
2.486
-7.096
4.728
-4.386
3.196
-7.465
7.096
-2.486
7.465
-3.196

Subject selection and results of analysis of the change in insulin concentration by
number of CHC interactions. For insulin, there were 1,031 subjects that had at least
one CHC interactions. Mahalanobis distance was generated replacing only CHC Y/N with the
number of CHC Interactions. Thirty-one subjects were identified with a MD > 22.46. These
subjects were removed prior to the statistical analysis. To ensure all groups had at least 10% of
the largest group, subjects with more than four interactions were combined in to one group, four
or more. Table 51 describes the demographics and change in insulin concentration for each CHC
interaction group.
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Table 51: Demographics and Change in Insulin Concentration for Subjects by Number of CHC
Interactions
Initial
Age

Sex

Initial BMI

Initial
Insulin )
(μU/mL)

Change in
Insulin
(μU/mL)

Mean
SD

54.4
13.1

36% M
64% F

29.6
6.38

11.6
7.7

-0.28
5.93

Mean
SD

56.4
13.2

36% M
64% F

29.8
6.08

12.1
6.7

-1.11
5.92

Mean
SD

57.6
13.0

27% M
73% F

31.0
6.89

12.6
8.7

-1.49
4.61

Mean
SD

57.8
13.3

30% M
70% F

32.1
6.55

12.8
7.2

-1.50
5.36

Mean
SD

55.5
13.2

34%M
66% F

30.0
6.43

11.9
7.5

-0.73
5.76

CHC
Interactions
1
N= 577
2
N =288
3
N =105
4 or more
N =110
Total
N =1000

Linear regression revealed a significant relationship between the mean change in insulin
concentration and the number of CHC interactions. Covariates were entered stepwise into a
linear regression model, with each subsequent model including the previous CVs and the newly
entered CV. The model summary table is shown as Table 52. The final model includes all
significant CVs and the DV. For insulin, initial insulin, accounted for 17.5% of the variance
explained. Initial BMI and sex were also explained 2.2%, and 0.4% of the variance respectively.
After adjusting for initial insulin, initial BMI, and sex, analysis confirmed a
statistically significant relationship between the mean change in insulin and the number of CHC
interactions (p = 0.01).
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Table 52: The Effects of Covariates and the Number of CHC interactions on the Significance of
Mean Change in Insulin
Model
1
2
3

4

Model
Components
Initial Insulin
Initial Insulin
Initial BMI
Initial Insulin
Initial BMI
Sex
Initial Insulin
Initial BMI
Sex
# of CHC Interactions

.175

R2
Change
.175

F
Change
211.510

.444

.197

.022

27.735

< 0.001

.448

.201

.004

4.702

0.030

.454

.206

.005

6.660

0.010

R

R2

.418

p value
< 0.001

Graphical representation (Figure 6) of the mean change in insulin suggests a downward
trend with each additional CHC interactions.

Figure 6: Mean Change in Insulin by Number of CHC Interactions
Error bars represent 95% Confidence Intervals

A Bonferroni multiple comparison table (Table 53) confirms no statistically significant
difference in the mean change in proinsulin between CHC interactions groups, (p >0.05).
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Table 53: Bonferroni Multiple Comparison for Insulin and Number of CHC Interactions
# of CHC
Interaction

Additional
Visit

Mean
Difference

Standard
Error

p value

1

2.00
3.00
4.00
1.00
3.00
4.00
1.00
2.00
4.00
1.00
2.00
3.00

.838
1.209
1.224
-.838
.372
.386
-1.209
-.372
.014
-1.224
-.386
-.014

.452
.611
.599
.452
.677
.667
.611
.677
.784
.599
.667
.784

0.384
0.289
0.249
0.384
1.000
1.000
0.289
1.000
1.000
0.249
1.000
1.000

2

3

4

95% CI of the
Difference
Upper
Lower
2.03
2.82
2.81
0.36
2.16
2.15
0.41
1.42
2.09
0.36
1.38
2.06

-0.36
-0.41
-0.36
-2.03
-1.42
-1.38
-2.82
-2.16
-2.06
-2.81
-2.15
-2.09

Subject selection and results of analysis of the change in C-peptide concentration by
number of CHC interactions. For C-peptide, 407 subjects had at least one CHC
interactions. Mahalanobis distance was generated replacing only CHC Y/N with the number of
CHC Interactions. Seven subjects were identified having a MD > 22.46 and removed prior to the
statistical analysis. To ensure all groups had at least 10% of the largest group , subjects with
more than four interactions were combined in to one group, four or more. Table 54 describes the
demographics and change in C-peptide concentration for each CHC interaction group.
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Table 54: Demographics and Change in C-peptide Concentration for Subjects by Number of
CHC Interactions
Initial
Age

Sex

Initial BMI

Initial
C-peptide

Change in
C-peptide
(ng/mL)

Mean
SD

55.3
13.5

33% M
67% F

30.3
6.6

2.98
1.36

-0.02
0.91

Mean
SD

55.3
14.7

38% M
62% F

29.7
4.8

3.13
1.37

-0.33
0.76

Mean
SD

59.8
13.4

28% M
72% F

31.4
7.5

3.11
1.33

-0.10
0.69

Mean
SD

59.3
14.6

20% M
80% F

30.5
5.8

3.16
1.59

-0.06
0.90

Mean
SD

56.2
13.9

32%M
68% F

30.3
6.3

3.04
1.38

-0.10
0.86

CHC
Interactions
1
n= 229
2
n=81
3
n=50
4 or more
n=40
Total
n =400

Linear regression revealed no significant relationship between the mean change in Cpeptide concentration and the number of CHC interactions
After adjusting for initial C-peptide, initial BMI, and age, no statistically significant
effect was detected for the mean change in C-peptide and the number of CHC interactions.
Covariates were entered stepwise into a linear regression model, with each subsequent
model including the previous CVs and the newly entered CV. The model summary table is
shown as Table 55. The final model includes all significant CVs and the DV. For C-peptide,
initial C-peptide accounted for 11.7% of the variance explained. Initial BMI and age also
explained 2.3%, and 1.0% of the variance respectively. The number of CHC interactions did not
statistically account for any variance explained. After adjusting for initial C-peptide, initial BMI,
and age, there was no statistically significant relationship between the mean change in C-peptide
and the number of CHC interactions (p = 0.435).
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Table 55: The Effects of Covariates and the Number of CHC interactions on the Significance of
Mean Change in C-peptide
Model
1
2
3

4

Model
Components
Initial C-peptide
Initial C-peptide
Initial BMI
Initial C-peptide
Initial BMI
Start Age
Initial C-peptide
Initial BMI
Start Age
# of CHC Interactions

.117

R2
Change
.117

F
Change
52.659

.374

.140

.023

10.595

0.001

.387

.149

.010

4.514

0.034

.388

.151

.001

.612

0.435

R

R2

.342

p value
< 0.001

Graphical representation (Figure 7) suggests a decrease in the mean change in C-peptide
between CHC interaction groups one and two, with an increase noted with groups three and four.

Figure 7: Mean Change in C-peptide by Number of CHC Interactions
Error bars represent 95% Confidence Intervals

104

A Bonferroni multiple comparison table (Table 56) confirms a statistically significant
difference in change in C-peptide between CHC interactions groups. A statistically significant
difference exist between groups one and two (p=0.035). No other statistically significant
differences were observed between the number of CHC interaction groups (p > 0.05).
Table 56: Bonferroni Multiple Comparison for C-peptide and Number of CHC Interactions
# of CHC Additional
Interaction
Visit
1

2

3

4

2.00
3.00
4.00
1.00
3.00
4.00
1.00
2.00
4.00
1.00
2.00
3.00

Mean
Difference

Standard
Error

p value

0.306
0.080
0.033
-0.306
-0.227
-0.273
-0.080
0.227
-0.047
-0.033
0.273
0.047

0.111
0.134
0.147
0.111
0.154
0.165
0.134
0.154
0.182
0.147
0.165
0.182

0.035
1.000
1.000
0.035
0.848
0.595
1.000
0.848
1.000
1.000
0.595
1.000

95% CI of the
Difference
Upper
Lower
0.600
0.434
0.422
-0.013
0.181
0.165
0.275
0.635
0.435
0.356
0.712
-0.528

0.013
-0.275
-0.356
-0.600
-0.635
-0.712
-0.434
-0.181
-0.528
-0.422
-0.165
0.435

Subject selection and results of analysis of the change in proinsulin concentration by
number of CHC interactions. There were 277 subjects that had at least one CHC
interactions. Mahalanobis distance was generated replacing only CHC Y/N with the number of
CHC Interactions with difference in health score. Seven subjects were identified with a MD >
22.46 and excluded prior to the statistical analysis. To ensure that all visit groups had at least
10% of the number of subjects in the largest group, subjects with more than four interactions
were combined in to one group, four or more. Table 57 describes the demographics and change
in Proinsulin concentration for each CHC interaction group.
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Table 57: Demographics and Change in Proinsulin Concentration for Subjects by Number of
CHC Interactions
Initial
Age

Sex

Initial BMI

Initial
Proinsulin
(pmol/L)

Change in
Proinsulin
(pmol/L)

Mean
SD

56.1
14.2

35% M
65% F

30.065
6.724

14.88
10.89

-1.07
8.43

Mean
SD

53.4
15.2

37% M
63% F

29.346
4.289

13.98
8.51

-1.79
5.69

Mean
SD

55.4
13.6

31% M
69% F

30.104
6.8270

12.59
8.19

-.07
5.65

Mean
SD

57.3
15.0

17% M
82% F

31.535
5.4504

18.75
13.84

-2.25
11.07

Mean
SD

55.5
14.4

33%M
67% F

30.051
6.19270

14.79
10.52

-1.21
7.94

CHC
Interactions
1
n= 161
2
n=56
3
n=29
4 or more
n=24
Total
n =270

Linear regression revealed no significant relationship between the mean change in
Proinsulin concentration and the number of CHC interactions. Covariates were entered stepwise
into a linear regression model, with each subsequent model including the previous CVs and the
newly entered CV. The model summary table is shown as Table 58.
Table 58: The Effects of Covariates and the Number of CHC interactions on the Significance of
Mean Change in Proinsulin

.189

R2
Change
.189

F
Change
62.377

.189

.000

.001

Model

Model Components

R

R2

1

Initial Proinsulin
Initial Proinsulin
# of CHC Interactions

.435
.435

2

p value
< 0.001
0.976

The final model includes all significant CVs and the DV. For proinsulin, initial accounted
for 18.9% of the variance explained. The number of CHC interactions did not statistically
account for any variance explained. After adjusting for initial proinsulin, there was
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no statistically significant relationship between the mean change in proinsulin and the number of
CHC interactions (p = 0.976).

Graphical representation (Figure 8) suggests a decrease in the mean change in proinsulin
between CHC interaction groups one and two and between groups three and four.

Figure 8: Mean Change in Proinsulin by Number of CHC Interactions
Error bars represent 95% confidence interval

A Bonferroni multiple comparison table (Table 59) confirms no statistically significant
difference in the mean change in proinsulin between CHC interactions groups, (p >0.05).
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Table 59: Bonferroni Multiple Comparison for Proinsulin and Number of CHC Interactions
# of CHC
Interactions

Additional
Visit

Mean
Difference

Standard
Error

p value

1

2.00
3.00
4.00
1.00
3.00
4.00
1.00
2.00
4.00
1.00
2.00
3.00

717
-.999
1.182
-.717
-1.717
.464
.999
1.717
2.181
-1.182
-.464
-2.181

1.235
1.606
1.742
1.235
1.821
1.942
1.606
1.821
2.197
1.742
1.942
2.197

1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000

2

3

4

95% CI of the
Difference
Upper Lower
4.00
-2.57
3.27
-5.27
5.81
-3.45
2.57
-4.00
3.12
-6.56
5.63
-4.70
5.27
-3.27
6.56
-3.12
8.02
-3.66
3.45
-5.81
4.70
-5.63
-3.66
8.02

Subject selection and results of analysis of the change in BMI by number of CHC
interactions. For BMI, 3,920 subjects had at least one CHC interaction. Mahalanobis
distance was generated replacing only CHC Y/N with the number of CHC Interactions. Sixtyfour subjects were identified with a MD > 20.52. These subjects were excluded prior to statistical
analysis. To ensure all groups had at least 10% of the largest group, subjects with more than four
interactions were combined in to one group, four or more. Table 60 describes the demographics
and change in BMI concentration for each CHC interaction group.
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Table 60: Demographics and Change in BMI for Subjects by Number of CHC Interactions
CHC
Interactions
1
n= 2142
2
n=919
3
n=376
4 or more
n=419
Total
n =3856

Initial Age

Sex

Initial BMI

Change in
BMI

Mean
SD

57.9
13.7

51% M
49% F

29.4
6.38

-0.34
2.18

Mean
SD

57.7
13.4

54% M
46% F

30.2
6.56

-0.57
2.27

Mean
SD

57.3
13.0

53% M
47% F

30.8
6.69

-0.63
2.41

Mean
SD

58.1
13.7

49% M
51% F

31.5
7.00

-0.94
2.35

Mean
SD

57.8
13.5

52%M
48% F

30.0
6.56

-0.49
2.25

Linear regression revealed no significant relationship between the mean change in BMI
and the number of CHC interactions. Covariates were entered stepwise into a linear regression
model, with each subsequent model including the previous CVs and the newly entered CV. The
model summary table is shown as Table 61. The final model includes all significant CVs and the
DV. For BMI, initial BMI accounted for 5.1% of the variance explained. The number of CHC
interactions did statistically account for some variance explained, 0.4%. After adjusting initial
BMI, analysis confirmed a statistically significant relationship between the mean change in BMI
and the number of CHC interactions (p < 0.001).
Table 61: The Effects of Covariates and the Number of CHC interactions on the Significance of
Mean Change in BMI
Model

Model Components

R

R

R2
Change

1
2

Initial BMI
Initial BMI
# of CHC Interactions

.226
.234

.051
.055

.051
.004

2
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F
Change

p value

206.969
15.104

0.000
0.000

Graphical representation (Figure 9) of the mean change in BMI suggests a downward
trend in change in BMI with each additional CHC interaction.

Figure 9: Mean Change in BMI by Number of CHC Interaction
Error bars represent 95% confidence interval

The Bonferroni multiple comparison table (Table 62) confirms a statistically significant
difference in change in BMI between CHC interactions groups. A statistically significant
difference in mean change was detected between CHC groups one and four, (p < 0.001) and
between groups two and four (p = 0.034). Decreases in the mean change in BMI was also seen
between groups one and two, between two and three, and between three and four, however the
change was not significant, (p > 0.05).
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Table 62: Bonferroni Multiple Comparison for BMI and Number of CHC Interactions
# of CHC
Interactions

Additional
Visit

Mean
Difference

Standard
Error

1

2.00
3.00
4.00
1.00
3.00
4.00
1.00
2.00
4.00
1.00
2.00
3.00

0.230
0.295
0.597
-0.230
0.064
.366
-0.295
-0.064
0.302
-0.597
-0.366
-0.302

0.089
0.126
0.120
0.089
0.137
0.132
0.126
0.137
0.160
0.120
0.132
0.160

2

3

4

95% CI of the
Difference
p value
Upper Lower
0.056
0.464 -0.003
0.114
0.626 -0.037
0.000
0.913 0.280
0.056
0.003 -0.464
1.000
0.427 -0.299
0.034
0.716 0.017
0.114
0.037 -0.626
1.000
0.299 -0.427
0.351
0.723 -0.119
0.000
-.280 -0.913
0.034
-0.017 -0.716
0.351
0.119 -0.723

Post-Hoc Analysis of Sample Size Requirements
Minimum sample size requirements are presented in Table 63. The mean changes and
SDs of those changes, along with the number of subjects in each group were used in the
determination of the Cohn’s D for all biomarkers and BMI. Soper’s online sample size calculator
generates sample size estimates using the estimated effects size, the desired statistical power
level, number of predictors, and a predetermined probability level. A power of 0.8 and
probability of 0.05 was used for all sample size calculations. The number of predictors was
determined by adding the number of CVs used in the ANCOVA to the DV. Table 63 describes
the samples size requirements for each biomarker. These requirements were met for each of the
analyses performed in this study.
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Table 63: Post-Hoc Sample Size Determination

Test

Glucose
Hemoglobin
A1c
1,5-AG
Insulin
C-Peptide
Proinsulin
BMI

Mean
Change
Non-CHC
Mean (SD)
-0.08
(13.31)
-0.11
(.39)
1.29
(3.64)
0.11
(5.31)
0.03
(0.73)
-0.23
(7.71)
0.20
(2.16)

Mean
Change
CHC
Mean (SD)
0.57
(12.77)
-0.10
(0.40)
0.37
(3.67)
0.78
(5.65)
0.11
(0.84)
1.17
(7.92)
0.49
(2.22)

Non
CHC
CHC
n
n

Cohen’s
D

Number Soper’s
of
Sample
Predictors
Size

964

962

0.049836

4

262

1295

1315

0.025314

2

378

117

25

0.251708

2

41

1010

973

0.122204

4

102

422

401

0.101662

4

122

249

274

0.179127

5

77

3912

3893

0.132408

2

75
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Chapter 5: Discussion

Chapter 5 provides an overview of the results stated in Chapter Four. This chapter
discusses the three Specific Aim and markers investigated within each aim. Clinical implications
and relation to the study hypotheses are presented. Finally, study limitations are discussed as
well as suggestions for future studies.
Discussion of the Study
This study was conducted to determine if there is a relationship between the changes in
subjects’ biomarkers of glucose homeostasis and BMI, and their interactions with CHCs.
Subjects’ laboratory results, demographics, whether or not they engaged in CHC interactions,
and if so, how many times, were obtained retrospectively from a laboratory in Richmond, VA.
There are reports that CHCs are effective at improving BMI and %HbA1c; but research on their
effectiveness at improving other markers of glucose homeostasis, such as insulin, C-peptide,
proinsulin, and 1,5-AG has not been published. Additionally, research relating the magnitude of
the change in BMI and biomarkers, and the number of CHC interactions, could not be found.
This study compared the change in BMI and biomarkers over a one-year period for two groups,
those who participated in CHC interactions, and those that did not.
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Specific Aim 1
The results of this portion of the study confirmed a statistical difference between those
who had CHC interactions and those who did not, but only for the average decrease in BMI.
Reductions in the mean BMI were consistent with the findings of Apple et al., in which weight
reductions were recorded over 24 months of various coaching styles (Apple et al. 2011).
Clinically significant weight loss is defined as a 5% reduction in body weight (Stevens et al.,
2006). In our study, the subjects’ initial weight was not extracted from the records; but the mean
change in BMI for the CHC interaction group was only - 0.49, suggesting that the changes were
not clinically significant.
For all seven markers, the initial values explained more of the variance in every statistical
model, than the use of CHCs, or any other CV. This suggests that initial marker value had the
most influence of the variables used in this study in predicting the change in mean maker values.
Random error accounted for the most variance. The only marker with a statistically significant
difference was BMI. The difference in BMI could have been explained by the large sample size.
BMI had almost three times the number of subjects than another marker. In addition, BMI was
the only marker directly measured at the time of collection. The phlebotomist or nurse measured
the patient’s height and weight at the time of visit. The results of BMI were not affected by the
same analytical sources of error as the other markers. Sources of error found with blood
collection, sample integrity, or analytical variations on the instrument were not a potential source
of error for the measurement of BMI. However, BMI could have been affected by variations in
the scales used for measuring weight or variations with the techniques used to measure height.
The increase in mean %HbA1c is discordant with the findings of Wayne & Rivito 2014,
Ko et al. 2007, and Battista et al., 2012. All three studies found that CHCs have a positive impact
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on glucose homeostasis as evidenced by the improvement in %HbA1c in their patients. Wayne &
Rivito utilized smartphone technology to accommodate subjects, and concluded that
communication and support improved %HbA1c. Ko et al. concluded that coaching lowered
%HbA1c. In addition, Battista et al. reported that dietitian education and guidance led to a 0.6%
reduction in %HbA1c, a common topic discussed with CHC interactions. The CHCs utilized in
this study had to be a registered dietician, exercise specialist, or registered nurse. The transition
from the BioRad Turbo to the Trinity HPLCE methodology could explain the increase. As noted
in the method comparison, the Trinity HPLC method did have a slightly positive bias compared
to the BioRad Turbo. The combination of methodology change and variation in calibrator could
be one factor for the increase. In addition, only a small percentage of variance was explained by
the CVs and the IV, the majority of variance was unaccounted for as random error.
The effects of CHC therapies on changes in 1,5-AG, C-peptide, insulin, and proinsulin
have not been published. As with the other markers, initial marker values accounted for the most
variance of the variables used in statistical analysis. This would suggest that initial marker value,
not the use of CHC interaction were more predictive of improvements in C-peptide, insulin, and
proinsulin. However, the improvement of insulin, C-peptide, and proinsulin in the both the CHC
and non-CHC groups could indicate an improvement of beta-cell health and therefore could
improve overall glycemic control.
In addition to testing the statistical significance of CHC interactions on the mean change
in markers, the clinical significance of the changes were also determined. Mean marker changes
were compared to the range of biological change to determine clinical significance. The initial
marker minimums and maximums were used to determine the absolute significant change by
determining the percent change for the minimum and maximum values. The percent biological
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variation for glucose, %HbA1c, insulin, and C-peptide were transformed to absolute values. The
mean of the transformed values were compared to the mean change in the observed CHC
interaction group. Clinically significant changes in biomarkers were not apparent for all subjects.
The mean changes calculated for glucose, HbA1c, and C-peptide were less than the calculated
mean absolute within marker changes (see Table 64). The changes in insulin, although not
statistically significant, may be clinically significant.
Table 64: Relationship Between Within-Subject Biological Variation and the Observed Mean
Change in Markers of Glucose Homeostasis for Subjects with CHC Interactions
Estimated
Absolute
Change
Mean
Lowest
Highest
Mean
Required
CVI
Range
Marker
Initial
Initial
Change
for
(%)
Change for
Result
Result
CHC
Significance
Significance
group
Glucose
5.6
52
331
(mg/dL)
Hemoglobin
1.9
4.1
9.9
A1c (%)
1
46
Insulin
14.6
(μU/mL)
C-Peptide
16.6
0.5
8.9
(ng/mL)
CVI = within-subject biologic variation
(Ricos, 2014)

0.57

5.8-37

10.7

0.10

0.16-0.38

0.14

0.78

0.3-13.26

0.50

0.11

0.16-7.7

2.0

Furthermore, the reagent lot-to-lot variation could be a source of variation. Table 65
describes the average bias of the reagent changes during the study timeframe. This could account
for some of the unexplained variance in the biomarker ANCOVAs.
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Table 65: Analytical Variation Observed with Reagent Change During the Study Timeframe

Test
Glucose
Hemoglobin A1c- BioRad
Hemoglobin A1c- Trinity
1,5-Anhydroglucitol
Insulin
C-Peptide
Proinsulin
Specific Aim 2

Number of
Reagent
lot-to-lots
30
34
N/A
18
7
7
13

Date Range

Average Bias
(%)

2012-2016
2012-2014
N/A
2013-2016
2012-2016
2012-2016
2012-2016

0.7
-0.3
N/A
1
-0.6
-1.5
-1

The results for blood glucose concentration and %HgbA1c were assigned a health score
based upon the established ranges for normal, prediabetes, and diabetes. Likewise, results for
BMI were assigned a health score based upon the established ranges for normal, overweight, and
obese.
Initial t-tests indicated that no statistical difference between the change in mean health
score for those who did and did not participate in CHC interactions exists for glucose or HbA1c
(p > 0.05). A statistically significant difference was found between the two groups for the
unadjusted mean change in BMI health score (p < 0.001).
Statistically significant differences in the changes in mean BMI health scores were found
between subjects with CHC interactions, and subjects without CHC interactions (p = 0.001).
However, the differences in the changes in health scores for glucose and %HgbA1c were not
significantly different between those groups of subjects. As was the case for the actual results for
these markers, more of the variance in the changes in health scores was explained by the initial
values for the markers. The low amount of variance accounted for by the CHC interaction group
and the study CVs suggests that a majority of the difference is explained by random error, as
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indicated by the analytical imprecision of the glucose and HbA1c assays and normal biological
variation.
There was a drop in the number of subjects classified as obese in both groups; but there
were more subjects with CHC interactions who showed an improvement in BMI classification
than those without CHC interactions. Health coach interactions are known to encourage weight
loss (Leahey & Wing, 2013, Appel et al., 2011). Therefore, it was expected to observe
improvements in weight and BMI that would result in a change in BMI health score. For the
glucose health score, there was a small decrease in the number of subjects classified as diabetic
in the group with CHC interactions, but no decrease in the group without CHC interactions. On
the other hand, there was a decrease in the number of subjects classified as normal by their
HgbA1c health score in both groups. One explanation could be the tendency of subjects to fast
before their blood draws, without improving their day-to-day lifestyle. These variations in diet
and activity can alter glucose results, potentially indicating an improved lifestyle. The HbA1c
assay is not affected by these variations, producing a more accurate indication of the subject’s
diet. Furthermore, the decrease in the normal classification could be explained by the change in
HbA1c assay methodology. The method comparison between the BioRad Turbo and Trinity
Premier HbA1c assays indicated a slight positive bias with the Trinity assay. Since the subjects
in the glucose, HbA1c, and BMI groups were different from the each other, comparison of the
trends between CHC and non-CHC groups was not possible.
For all of the markers and health scores, the standard deviations in the changes in these
parameters were much larger than the mean changes. This, along with the small percentage of
the variances in the changes that was explained by CHC interactions, suggests that there were
other factors that influenced the behaviors and changes in the markers of the subjects in both
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groups. These factors could include prescribed medications, dietary habits, or exercise routines.
All study subjects were provided with the same laboratory report, which included information on
their overall health. The results of this study suggest that some individuals need CHCs for
motivation to move through the stages of the TTM towards a healthier lifestyle, while others are
self-motivated to do so.
Specific Aim 3
There was a statistically significant relationship between the magnitude of change in
marker results and the number of CHC interactions, but only for insulin and BMI after the effects
of the covariates were taken into account. The known relationship between increases in BMI and
insulin resistance (Chung, Cho, Chung, & Chung, 2012) could explain why of the number of
CHC interactions affected change in Insulin and BMI and not the other markers. However, not
all subjects in the insulin marker group may have been in the BMI group and vise-versa. As with
the changes in marker values and changes in health scores, the initial marker values explained
more of the variance in those changes than any other covariate or CHC interactions.
In the case of the mean change in %HbA1c, there was an increase in %HbA1c regardless of the
number CHC interactions, which is not consistent with the changes in insulin concentration and
BMI. However, there was a transition from the BioRad Turbo Variant to the Trinity Premier
Boronate affinity HbA1c testing platforms during the study period that could explain this
observation.
Glucose and proinsulin are both sensitive to fasting status. If a subject ate or drank
something during a fasting period, a falsely increased glucose or proinsulin could have been
present. For not just glucose or proinsulin, if a subject misrepresented their fasting status or the
duration of fasting, variations in all biomarkers with the exception of HbA1c and 1,5-AG could

119

be present as well. The inability to confirm fasting status in the study poses a limitation for all
three Aims.
Conclusions
For all three Specific Aims in this study, there was a significant difference in the mean
changes in BMI between patients who had CHC interactions and those who did not, as well as
between patients with different numbers of CHC interactions. None of the other markers of
glucose homeostasis showed consistent, significant differences between subjects in those groups.
The initial BMI and initial biomarker values also showed consistent and significant effects across
all three Specific Aims, and appear to be a more powerful motivators for change than CHCs
alone.
Limitations
The first limitation of the study is the uncertainty of additional activities the subjects
might have engaged in during the study timeframe. Neither the LIS database nor the CHC
interaction database contains information on other resources/interventions the subjects might
have utilized. Therefore, differences in training and credentials, coaching style, length of
interactions, approachability, or recommended strategies specific to each coach may have
affected the marker results.
Comorbidities in the study subjects were also not available for the data analysis.
Diagnosis of diabetes or insulin resistance prior to being seen be the CHC could affect the study
subjects’ expectations or views of the CHC interactions. Subjects may have had diseases other
than diabetes such as cardiovascular, liver, or kidney disease that could have affected their ability
to control their glucose homeostasis. Liver and kidney diseases can also affect the clearance of
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the markers and affected the results. In addition, mental and/or physical conditions could limit or
inhibit the study participants’ ability to adhere to CHC recommendations.
The inability to confirm that subjects followed the recommendations of the CHCs is also
a limitation of this study. Whether or not subjects were actually fasting at the time of the blood
collections could also not be confirmed. In addition, subjects’ motivation to change their own
behavior and improve glucose homeostasis was not measured. As mentioned earlier, a change in
the methodology for measuring %HbA1c occurred during the study period, and may have
introduced a bias in the follow-up results for some subjects.

Recommendations for Future Studies
The advantages of a retrospective such as reduced cost, availability of study subjects and
data, and fewer IRB restrictions, also come with disadvantages. A prospective study could ensure
that the sample size is the same across all biomarkers, as well as between the control and
intervention groups. This would allow for multivariate analysis of the biomarkers to investigate
the overall effect of the CHCs on changes within and across biomarker groups. Future studies
should identify subjects with comorbidities, medications, or other therapies that could impact the
measurement of the markers or changes in their results. Future studies should also standardize
the CHC interactions, themselves. Finally, it would be recommended not include subjects whose
study timeframe included a methodology change.
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